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ABSTRACT
THEORETICAL AND EXPERIMENTAL STUDIES ON
MANIPULATION OF FLUORESCENCE BY GOLD NANOPARTICLE:
APPLICA TION FOR MOLECULAR IMAGING
Jianting Wang
December 2011
Gold nanopartic1es (GNPs) have shown beneficial properties for biomedical use,
e.g., their non-toxic nature and surface properties for easy modification. Upon receiving
light, they generate a strong surface plasmon field, which can alter the fluorescence of
fluorophores. The level and type of the fluorescence alteration depend on the GNP size
and shape, excitation (Ex)/emission (Em) wavelengths and quantum yield of the
fluorophore, as well as the distance between the fluorophore and GNP.
In this dissertation, the effect of the properties listed above on the fluorescence
output was theoretically analyzed for the fluorophores frequently used in biomedical
studies. For fluorescence quenching, fluorophores with the Em wavelength near the GNP
plasmon resonance peak (520 nm) are better suited. As the Em wavelength increases, a
shorter distance is required for achieving the same level of quenching. A bigger GNP
requires shorter distance for quenching. To obtain fluorescence enhancement, the Em
wavelength of the fluorophore needs to be longer than the GNP plasmon resonance peak
(e.g., > 650 nm). The fluorophore with lower intrinsic quantum yield tends to be
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enhanced more. The GNP needs to be sufficiently large (> 5 nm), and a bigger GNP
provides a higher maximum enhancement.
Utilizing the quenching/enhancement ability of GNPs, a near-infrared (NIR)
contrast agent that emits fluorescence at a higher level only at the particular cancer site
was developed. Cypate, a safe NIR fluorophore, was selected as the fluorophore because
NIR penetrates deeper into tissue and because Cypate is non-toxic. Cypate was
conjugated to a GNP via two spacers. One is short for the quenching and with a substrate
for a breast cancer-specific enzyme, urokinase-type plasminogen activator (uPA). The
other is a long, biocompatible polymer chain for fluorescence enhancement. The
fluorescence of the contrast agent was quenched by GNP by 93%. In the presence of uP A,
the short spacer was cleaved and the remaining long spacer enhanced fluorescence 1.8
times.
The study results are beneficial for developing efficacious optical contrast agents.
This novel contrast agent can detect and diagnose breast cancer with high specificity and
sensitivity, as FRET or molecular beacon but with a higher sensitivity and without the
restriction of using DNAIRNA segments.

vii

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS······································································
ABSTRACT··························································································
LIST OF TABLES··················································································
LIST OF FIGURES·················································································

IV
VI
Xl

Xll

CHAPTER
I. INTRODUCTION .................................................................... .
II. BACKGROUND .......................................................................

4

A. Fluorophores' ....................................................................... , .

4

1.
2.
3.
4.

Small organic molecules······················································
Quantum dots ....................................................................
Fluorescent proteins' . ....... .. .. .... .. ......... .. .... ........... .. ........ ... ..
Specially designed fluorescent probes ..... ...... .... ..... .......... .......

6
8
10
11

B. Metal nanoparticles and fluorescence .................. , .......... ..............

13

1. Surface plasmon field of metal nanoparticles:····························
2. Fluorescence alteration by gold nanoparticles ..... .......... ..... ........

13
14

C. Theory of fluorescence alteration by metal nanoparticles .................

16

1. Main mechanisms and parameters involved ..............................
2. Mathematical model for plasmon field strength near a GNp·········
(a) Plasmon field
(b) Fluorescence change of a fluorophore near a GNP

16
18

D. Nanoparticles for biomedicine ................................................... : 26
1. Advantages of nanoparticles for biomedical application··············· 26

Vlll

2. Types of nanopartic1e ............................................................. 27
(a) Organic nanopartic1es
(b) Inorganic nanopartic1es
E. Fluorescence alteration by GNP studied by the Kang group·············· .. 34

III. MATERIALS, INSTRUMENTS, AND METHODS
A. Theoretical study ........................................................................ 37
B. Syntheses of molecular spacers and modification of Cypate ................. 38
1. Materials ............................................................................ 39
2. Instruments·········································································· 39
3. Methods·············································································· 40
(a) Synthesis of the short spacers
(b) Conjugation of Cypate to short spacers
(c) Synthesis of long spacers
(d) Modification of Cypate
C. Conjugation of Cypate to GNPs ..................................................... 44
1. Materials ............................................................................ 44
2. Instruments .......................................................................... 44
3. Methods .............................................................................. 45
(a) Handling ofthiolated materials
(b) GNP surface modification and Cypate conjugation
D. Cell study .................................................................................. 48
1. Materials ............................................................................ 48
2. Instruments·········································································· 49
3. Methods·············································································· 49
(a) Quantification of uPA in cell media by ELISA
(b) Cell studies with GNP-SSP-Cy
(c) Cell studies with GNP-LSP-mCy
IV. RESULTS AND DISCUSSION ..................................................... 52
A. Theoretical Analysis of Ruorescence Alteration by GNP ................... 53
1. Excitation Rate and System Parameters····································· 53

(a) GNP size and incident light wavelength
(b) Effect of coating material on GNP

IX

2. Quantum Yield Affected by Various Parameters····················· ....... 56
(a) Radiative decay rate
(b) Absorption
(c) Intrinsic quantum yield
3. Resulting Fluorescence Output·················································· 60
4. ICG Fluorescence Affected by GNPs··········································· 63

B. Experimental Study ...................................................... ················67
1. Components of the contrast agent···· ........................................... 67
(a) GNP
(b) GNP surface modification
(c) Spacers
(d) Fluorophore
(e) Targeting molecule
2. Characterization of components ................................................. 71
(a) The effect of the solvent on Cypate fluorescence
(b) Cypate concentration and self-quenching
(c) Fluorescence of free Cypate affected by free GNP colloids
3. Optimization of spacers ........................................................... 75
(a) Short spacer
(b) Long spacer
(c) Dual-spacer
4. Cell study···· ......................................................................... 97
(a) Short spacer performance
(b) Long spacer performance
V. CONCLUSIONS ...................................................... ··················103
VI. FUTURE WORK ...................................................... ·················107
REFERENCES ........................................................................................ 109
APPENDIX ............................................................................................. 122
A. Fluorescence enhancement in biosensing ........................................ ·122
B. Hollow gold nanospheres for conditional fluorescence quenching········· ·133

CURRICULUM VITAE ...................................................... ·········139

x

LIST OF TABLES
PAGE

TABLE

1. Fluorophores studied, and their excitation/emission peak
wavelengths and intrinsic quantum yields ................................................... 37

2. Molecular spacers used for conjugating Cypate to GNPs ............................... ·38

3. Normalized radiative decay rate and absorption rate at 0.1,5 and
10 nm from a 30 nm GNP surface, and (l_qO)/qO of the
fluorophores ........................................................................................ 58
4. Spacers used and their estimated lengths by molecular simulation .................... 84

5. Size of nanoparticles, before and after conjugation of sPEG and
sPEGILSPs, measured by light scattering particle size analyzer. ..................... 84

Xl

LIST OF FIGURES
PAGE

FIGURE

1. Mechanisms (a and b) and the parameters (1 ~4) involved in the
fluorescence alteration by GNPs. ............................................................ 17
2. (a) The coordinates used in the computation of the plasmon field strength
on and around a GNP and (b) a schematic diagram of a GNP with
polymer coating in a medium. ............................................................... 19
3. GNP stabilized with (a) large polyethylene glycol molecules and
(b) with small aliphatic-PEG molecules. .................................................. 31
4. The enhancement in the excitation decay rates of fluorophores by their
respective Ex wavelengths, with respect to the distance from the surface of a
(a) 10 nm (b) 30 nm and (c) 50 nm GNP ................................................. 54
5. Plasmon field distributions computed on/around a 10 nm GNP coated
with PEG, at a thickness of 0, 1,2, or 3 nm, when the incident
light at 780 nm is applied.······································································ 55
6. Absorption rate ( Yahs / y;') of various fluorophores by a 30 nm GNP,
with respect to the distance from the GNP surface. .................................... 57
7. Theoretically computed quantum yield of (a) various fluorophores
(b) ICG with respect to the distance from a 30 nm GNP. ............................. 59
8. Theoretical estimation of fluorescence output of various fluorophores
affected by (a) 10 (b) 30 and (c) 50 nm GNP ........................................... 61
9. The enhancement in the excitation decay rates oflCG
(Ex wavelength 780 nm) by GNPs at various sizes. .................................... 63
10. (a) Absorption rate (Y"h, / y;') oflCG by a 30 nm GNP, with respect to the
distance from the GNP surface (b) magnified view of the section
in the rectangle in (a) ........................................................................... 64

Xll

11. Theoretically computed quantum yield oflCG (Ex/Em 780/830 nm)
with the distance from the GNP at various sizes. ...................................... 65
12. Theoretically computed fluorescence emission ofICG (Ex/Em 780/830 nm)
with the distance from the GNP at various sizes. ..................................... 66
13. (a) Design of highly cancer specific fluorescing cancer locator
The agent normally does not emit fluorescence because the
short spacer place Cypate very close to the GNP. (b) When the cancer
locater binds to the cancer cell, the short spacer is cleaved by enzyme
from cancer cell and the fluorescence is emitted at an enhanced level. .......... 67
14. Molecular structures of (a) ICG and (b) Cypate (c) m-Cypate .................... 70
15. Fluorescence ofCypate in water, 1 and 10 mM PBS buffer. ....................... 72
16. Fluorescence of Cypate at various Cypate concentrations ........................... 73
17. Fluorescence of free Cypate with various concentrations of free GNP .......... 74
18. Schematic diagram for fluorescence of free Cypate affected
by (a) high and (b) low GNP concentration in solution............................. 75
19. A schematic diagram of the uP A triggered fluorescence contrast agent,
Cypate conjugated GNP via a short spacer: (a) normally emits little
fluorescence (b) in the presence of uP A enzyme, the spacer is cleaved
and the fluorescencing ability of the agent is restored ................................ 76
20. (a) Absorption spectra of GNP, sSP-Cy and GNP-sSP-Cy, and (b) TEM
image ofGNP-sSP-Cy [GNP, 8.0 nm]. .................................................. 77
21. Relative fluorescence of the GNP-SSP-Cy with the core GNP size of
3.7,8.0 and 16.4 nm at 10 11M Cypate concentration in PBS buffer. ........... 78
22. Theoretical estimation of fluorescence emission with the distance from
the GNP surface for the GNPs sizes at 3.7,8.0, and 16.4 nm
for ICG (Ex/Em 780/830 nm). . .......................................................... 79
23. The relative fluorescence levels of GNP-SSP-Cy with 3.7
(GNP concentration 31 nM) and 8.0 nm (GNP concentration 7 nM)
GNPs at 10 11M Cypate in PBS buffer, before and after adding uPA.
Reaction time: 5 min; ExlEm: 780/830 nm ............................................ 81
24. Fluorescence of GNP-nSSP-mCy with 8.0 nm GNP at various GNP
concentrations, before and after adding uP A, Reaction time: 5 min;
Ex/Em: 780/830 nm ......................................................................... 82

Xlll

25. TEM image of8.0 run GNPs coated with (a) sPEG only and (b) sPEG
and C12PEG6 ................................................................................. 85
26. Absorption spectra of 8.0 run GNP, GNP coated with sPEG alone,
with sPEG and C12PEG6, GNP-LSP-mCy, and mCy ............................... 86
27. Schematic diagram of the function of blocking agent. .............................. 88
28. Relative fluorescence ofmCy conjugated to 8.0 run GNP via spacers
with various lengths. ......................................................................... 89
29. Relative fluorescence ofmCy-BLK conjugated to 8.0 run GNP via
the spacers with various lengths, compared to the theoretically
estimated fluorescence. ...................................................................... 90
30. Relative fluorescence emjamcement ofmCy
conjugated to (a) 3.7 (b) 8.0 and (c) 16.4 run GNPs via spacers
with various lengths, compared to the theoretically estimated
fluorescence level. ............................................................................. 91
31. Original design for the synthesis of GNP-DSP-mCy (ideal case) ................. 94
32. Potential undesired product (a) incomplete conjugation (b) cross linking
from the original design for the synthesis of GNP-DSP-mCy . ...................... 94
33. The chemical structure of the ring-shaped dual spacer (rDSP) . .................... 95
34. Absorption spectra of 8.0 run GNP, GNP coated sPEG,
GNP-rDSP-mCy, and mCy ....................................................... ··········96
35. Fluorescence ofGNP-rDSP-Cy (8.0 run GNP) at 100 nM Cypate,
0.9 nM GNP, before and after adding uPA at 1030 units/ml
(Ex/Em 780/830 nm) ......................................................................... 97
36. uPA concentrations in the media containing MCF-7 (uPA-) or
MDA-MB-231 (uPA+) cells, after 8 and 32 hrs of cell culturing ................ 99
37. Fluorescence ofGNP-SSP-Cy in media without cells, with
MDA-MB-231 cells, and with MCF-7 cells after 2 hr incubation.
Ex/Em: 780/805-830 nm. ................................................................... 100
38. Fluorescence ofCypate and GNP-LSP-mCy in (a) MCF-7 (uPA-)
and (b) MDA-MB-231 (uPA+) cells, 1,3 and 24 hrs after the treatment. ...... 101
39. Fluorescence ofCypate and GNP-LSP-mCy in (a) MCF-7 (uPA-) and
(b) MDA-MB-231 (uPA+) cells, 1, 3 and 24 hrs after the treatment. ............ 102

XIV

CHAPTER I
INTRODUCTION
Fluorophores have been extensively used as a signal mediator in the biomedical
research and disease diagnosis/prognosis. Artificial manipulation of the fluorescence of a
fluorophore can be highly beneficial for improving the specificity andlor sensitivity of
biosensing/bioimaging. For example, fluorescence quenching can be used for negative
sensing or for conditional de-quenching to increase specificity. Fluorescence enhancing
can improve sensitivity and the signal to noise ratio.
Since fluorescence is generated by the electrons that are excited by photonic
energy, a localized entity affecting the electron state of the fluorophore can change the
fluorescence output. Nano-sized metal particles forming a strong electromagnetic
(plasmon) field upon receiving photonic energy can be, therefore, good candidates for
this purpose [Lakowicz, 2005; Zayats, et al., 2005; Evanoff and Chumanov, 2005]. Gold
nanoparticles (GNPs) are one of the most attractive metal nanoparticles for biomedical
applications for this purpose because they are chemically stable and non-toxic and also
because the gold-thiol chemistry for surface conjugation of biomolecules is well
established [Connor, et al., 2005; Love, et al., 2005; Shukla, et al., 2005],
Fluorescence quenching and enhancement using GNPs have been explored by
many researchers. The type and the level of fluorescence alteration by GNPs depend on
parameters including the metal type, particle size; the excitation and emission
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wavelengths and the quantum yield of the fluorophores; and the distance between the
fluorophore and the particle. In this dissertation, the effect of these parameters on the
plasmon field distribution of GNPs and on the fluorescence alteration was analyzed for
commonly used fluorophores in biomedical studies. The study result is expected to
provide information for selecting fluorophore, GNP size, distance between the
fluorophore and the GNP, in designing the efficacious contrast agents for molecular
Imagmg.
In parallel to the theoretical analyses, a safe, near-infrared (NIR) contrast agent
for cancer detection was developed. The contrast agent specifically targets the cancer
cell, and it emits fluorescence, only in the presence of the enzyme secreted by a particular
breast cancer type, at a highly enhanced level. Thus, it provides high specificity and
sensitivity for cancer detection. It can also be used to characterize the cancer type
(diagnosis) by its ability of recognizing the particular enzyme. The same approach can
also be used for other disease diagnoses. This contrast agent can be potentially combined
with cancer treatment function (e.g., photo-dynamic therapy, hyperthermia) to enable
seamless diagnosis and treatment.
The structure of this dissertation after this introduction is as follows:
Chapter II presents the BACKGROUND information on the fluorophore, metal
(especially gold) nanoparticles, fluorescence quenching and enhancement by GNPs, and
the mechanism and mathematic models of fluorescence alteration by GNPs.
Chapter III describes the MATERIALS, INSTRUMENTS, AND METHODS
used in theoretical and experimental studies.
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Chapter IV contains the RESULTS AND DISCUSSIONS of the theoretical
analyses of the factors affecting fluorescence alteration by GNP, and the experimental
study of fluorescence quenching, restoration, and fluorescence enhancement of Cypate by
GNPs.
Chapter V concludes (CONCLUSIONS) the studies performed.
In Chapter VI, suggested FUTURE WORKs are presented.
In the APPENDIX, the application of gold nanoparticle reagent in our fiber-optic
biosensing system, and fluorescence alteration of Cypate by hollow gold nanosphere are
presented.
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CHAPTER II

BACKGROUND

A. FLUOROPHORES
Fluorophores are molecules that absorb light at a particular wavelength and emit
light at another but equally specific wavelength [Hercules, 1966]. The process is such
that the electrons of the fluorophore absorb photons and the photons raise the energy
level of the electrons to an excited state. During the excitation period, some of the energy
is dissipated by molecular collisions or transferred to a proximal molecule, and then the
remaining energy is emitted as photons to relax the electrons back to their ground state.
Because the emitted photons usually carry energy less than the one received, they are
emitted at a longer wavelength. The wavelength shift between the excitation and
emission lights is called the Stokes Shift and each fluorophore has its distinct
characteristic Stokes shift. If the Stokes Shift is very small and the excitation and
emission wavelengths greatly overlap, the detection of emitted fluorescence can be
difficult to distinguish from the excitation light. Conversely, fluorophores with large
Stokes shifts are easier to use because the two can be distinguished better [Lakowicz,
2006]. Since the emitted light (fluorescence) can be distinguished from the excitation
light and is at a particular wavelength, one can use it as an optical signal [Hercules, 1966;
Rendell, 1987; Guilbault, 1990]. Fluorophores have been, therefore, extensively used in
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biosensing and imaging for detecting biomolecules, monitoring/studying biological
processes, diagnosing/prognosing diseases, etc. [Choy, et ai., 2003].
Early studies using fluorophores employed those emitting the light mainly in the
visible range of the electromagnetic spectra (e.g., 400-700nm) because of the limitation
in detection. The advancement in technology has allowed the fluorescence detection
beyond the visible spectra and into the ultraviolet (UV, e.g., 10-400 nm) and near infrared
(NIR) ranges (e.g., 700-900 nm). The new fluorophores and detectors offer greater
variability, versatility, and multiplexing capabilities.
The quantum yield (QY) of a fluorophore is the ratio of the number of photons
emitted as fluorescence to that of the photons absorbed, i.e., the emission efficiency of
the fluorophore [Lakowicz, 2006]. QY is unique for each fluorophore. In sensing or
imaging applications, fluorophores with higher QY is desired because they provide
greater sensitivity.
Photostability is another important property of a fluorophore. When a fluorophore
IS

exposed to an excitation light, the fluorescence level decreases over time due to

photon-induced chemical damage, and the decrease in the fluorescence is called
photobleaching [Lakowicz, 2006]. Photostability is very important for optical imaging,
especially in optical microscopy where the excitation light intensity is high.
Other important properties of fluorophores may include functional groups for
bioconjugation, water-solubility, toxicity, pH-sensitivity, etc. Depending on the
application, the fluorophore with desired properties needs to be carefully selected.
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1. Small Fluorescent Organic Molecules

Small fluorescent organic-molecules are often called organic dyes. Organic dyes
are small molecules, at the scale of ~0.5 nm [Resch-Genger, et ai., 2008]. The small size
of these fluorophores is an advantage for bioapplications because they can be conjugated
to macromolecules, such as antibodies, biotin or avidin, without interfering with their
biological function. The first fluorescent compound used in biological research was
Fluorescein synthesized by Adolf von Baeyer in 1871 [Guilbault, 1990; Resch-Genger, et

ai., 2008; Zhang, et ai., 2002; Waggoner, 2006]. Fluorescein is still widely used today
and its derivatives have been produced to improve their photostability and solubility.
Currently a wide variety of dyes are available with various excitation/emission spectra,
optimal quantum yields, excitation coefficients and functional groups for conjugation are
available. Examples include rhodamine (TRITC), coumarin, cyanine, Alex Fluors, and
their derivatives [Rietdorf, 2005].
NIR fluorophores have attracted much attention especially in optical imaging of
human because they offer several advantages over the fluorophores in the visible range.
NIR is absorbed less by biological tissues than the visible light. In tissue, there is less
autofluorescence in NIR than in the visible range, thereby less background noises
[Kobayashi, et ai., 2002]. In the infrared region, photons are absorbed by water much
more than in NIR. NIR, therefore, provides a window of opportunity with deeper tissue
penetration, i.e., 2-4 centimeters [Marshall, et ai., 2010]. Compared to other commonly
used imaging techniques, such as magnetic resonance imaging (MRI), computed
tomography (CT), and photon emission tomography (PET), optical imaging is more
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sensitive, more cost-effective, rapid, and easy to use [Choy, et aI., 2003; Cassidy and
Radda, 2005; Mankoff, 2008, Marshall, et ai., 2010].
The early NIR imaging usually used angiogenesis-mediated absorption contrast.
The absorption of NIR light in a typical tissue having 8% blood volume and 29% lipid
content, the dominant absorber is hemoglobin, accounting for 39-64% of total absorbance
at NIR wavelength [Lim, et ai., 2003]. NIR optical tomography using time-dependent
measurements of light propagation in the breast has been developed for breast cancer
screening for two decades [Kang, et aI., 1993; Ntziachriostos and Chance, 2001; Honar
and Kang, 2002; Wang, et ai., 2010]. There has been remarkable advance in the
application of NIR on detecting the angiogenesis and increased hemoglobin absorbance
for contrast. However, the angiogenesis-mediated absorption contrast only for optical
mammography reduces the potential for using NIR techniques to assess sentinel lymph
node staging, metastatic spread, and multifocality of breast disease [Frangioni, 2003;
Hawrysz and Sevick-Muraca, 2000]. Recent research has been focused on the use of
contrast agents for the molecular-based, diagnostic imaging [Marshall, et aI., 2010].
Exogenous, optical contrast agents for human use have been limited to the safe
organic dyes. In 1959, Indocyanine green (lCG) was approved by the United States Food
and Drug Administration (FDA) as a contrast agent for retinal angiography for both
absorption and fluorescence imaging. Currently, it still remains the only FDA-approved
NIR fluorophore [Alford, et ai., 2009; Marshall, et ai., 2010]. Fluorescent imaging with
ICG has been used for the vascular mapping and tissue perfusion measurement
[Frangioni, 2003]. ICG angiography is a routine test in the ophthalmology clinic for
detecting the posterior uveitis [Herbort, et aI., 1998] and central serous chorioretinophthy
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[Chen, et ai., 1999]. ICG has been also used to image the vasculature [Raabe, et ai.,
2003] and cerebrospinal fluid in brains [Sakatani, et ai., 1997] of both rats and human,
for improved tumor localization and the assessment of post-resection margins with high
sensitivity and specificity [Haglund, et ai., 1994]. It has also been studied for sentinel
lymph node mapping for cancer staging in breast, skin and gastric cancers [Marshall,
2010].

2. Quantum dots

Quantum

dots

(QDs)

are

semiconductor

nanocrystals

and

fluorescent

nanoparticles (2-10 nm) that contain a core of the group II and VI elements or group III
and V elements [Gao, 2005; Medintz, 2005]. CuCI nanocrystals in colloidal solutions are
first discovered in the 1980s by Alexei Ekimov [1981] and by Rossetti [1983], and the
term "quantum dot" was first used by Mark Reed [1988]. In 1993, Murrays, et ai. [1993]
developed the procedure for synthesizing of high-quality CdSe QDs dispersed in organic
solvents.
In QDs, the excitons are confined in all three spatial dimensions due to the small
size of the particle. Therefore, the electronic characteristics of these particles are closely
related to the size and shape of the individual crystal. Generally, smaller QD results in
larger band gap, which means the difference in energy between the highest valence band
and the lowest conduction band is greater. Therefore, more energy is needed to excite the
QD, and thus, more energy is released

whe~

the crystal returns to its resting state. As a

result, by changing the size and shape of the particle, the excitation and emission
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wavelengths can be tuned, typically from the visible to NIR range [Reed, et aI., 1988;
Wang, et aI., 2001; Michalet, et ai., 2001; Altinoglu and Adair, 2010].
Compared to organic dyes, QDs have higher quantum yield [>50%, West and
Halas, 2003] and higher molar extinction coefficients, e.g., roughly an order of
magnitude higher than even the strongly absorbing Rhodamine 6G [Leatherdale, et ai.,
2002; Smithpeter, et ai., 1998]. As a result, they emit brighter fluorescence (most QDs
are approximately 10-20 times brighter) than organic dyes [Dabbousi, et ai., 1997; Chan
and Nie, 1998]. Since the light absorption by QDs is greater at a shorter wavelength
(higher energy), QDs exhibit an almost continuous, broad-band absorption and a narrow
emission spectrum, resulting in a large effective Stokes shifts [Cai, et ai., 2007; Michalet,
et ai., 2005]. Therefore, the excitation and emission spectra of QDs are well separated.
QDs also exhibit photostability higher than organic dyes [Santra and Dutta, 2007].
QDs became fluorescent probes for the biosystem in 1998 when two groups
simultaneously reported the procedures for making water-soluble QDs and conjugating
them to biomolecules [Chan and Nie, 1998; Bruchez et aI., 1998, Mazumder, et ai.,
2009]. Since then, extensive research has been directed toward using QDs in biosensing
and bioimaging. QD labeled microorganisms, biomarkers, cancer cells, etc. have been
studied in detecting biomolecules and in disease diagnosis, but not in humans
[Mazumder, et ai., 2009]. Even though NIR QDs have a great potential, there are only a
few reports for in vivo NIR imaging using QDs [Altinoglu and Adair, 2010], and all of
these reports employed QDs as a tracer in sentinel lymph node mapping. Although some
researchers assert that the surface modification of QDs may eliminate the potential harm
[Gerion, et aI., 2001; Altinoglu and Adair, 2010; Resch-Genger, et aI., 2008], the
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cytotoxicity to organelles and membranes, induced apoptosis, and peroxidative stress, are
still serious concerns in using QDs for human [Jaiswal and Simon, 2004; Hoshino, et aI.,
2004; Ballou, et aI., 2004; Ryman-Rasmussen, et al., 2007].

3. Fluorescent proteins

Green fluorescent protein (GFP) was originally isolated from the light-emitting
organ of the jellyfish Aequorea victoria by Shimomura, et aI., in 1962. Thirty years later,
Chalfie, et al. [1994] characterized the DNA encoding of GFP and used it as a gene
expression reporter. In 2006, Martin Chalfie, Osamu Shimomura, and Roger Y. Tsien
shared a Nobel Prize in Chemistry for their discovery of GFP. Since then, derivatives of
the GFP and many other fluorescing proteins were developed in biological expression
systems, and they are now frequently used in biological research [Choy, et aI., 2003]. The
benefit of using this type of fluorophores is that the plasmid expression can be introduced
into cells, organs or organisms, to express the fluorophore either alone or fused to the
protein of interest in the biological processes studied [Miyawaki, et aI., 2003]. However,
the use of fluorescent proteins can be time consuming, and also expressing large amounts
of light-producing proteins can cause reactive oxygen species, introducing artifactual
responses or toxicity. In addition, the size of the fluorescent protein may change the
biological function of the cellular protein to which the fluorophore is fused. Biological
fluorophores do not typically provide the level of photostability and sensitivity offered by
synthetic fluorescent dyes [Prasher, et aI., 1992; Kain, et aI., 1995; Choy, et al., 2003].
In terms of the usage of fluorophores for human, until now, only a few organic
dyes are used for human due to the safety issue [Kovar, et al., 2007]. Although several
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organic dyes are used for in vivo animal studies, for humans, only fluorescein and ICG
were approved by the US FDA [Alford, et aI., 2009], and for NIR, ICG is the only one.
Cypate, a derivative of ICG, is demonstrated to be non-toxic to animals up to 10
Ilmol/kg, and considered to be a "biocompatible" dye [Achilefu, et aI., 2002], although it
has not yet been submitted for FDA approval.

4. Specially designed fluorescent probes
The fluorescence emission level can be influenced by interactions with other
fluorescing or non-fluorescing molecules. These interactions can be beneficially used to
design probes highly specific to a particular biomolecule for biosensing or molecular
imaging, in such a way that the fluorescence level or emission wavelength changes in the
presence of the biomolecule. The most frequently used fluorescent probes include the
molecular beacon and the fluorescence resonance energy transfer (FRET, also known as
Forster resonance energy transfer).
Molecular beacon was first developed by Tyagi and Kramer [1996]. In the
molecular beacon. a fluorophore and a quencher are attached to the two ends of a hairpinshaped oligonucleotide. When a fluorophore is in contact with a quencher, the energy
from excitation is transferred to the quencher, and this energy is then lost by heat
[O'Reilly, 1975]. In the absence of a complimentary target sequence, the beacon remains
closed and there is no appreciable fluorescence. Once the single stranded loop portion of
the hairpin hydridizes to the target sequence. the resulting spatial separation of the
t1uorophore from the quencher leads to fluorescence emission. Molecular beacons have
become widely used in chemistry, biology, biotechnology and medical sciences for the
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particular biomolecular recognition, due to the easy synthesis, molecular specificity and
structural tolerance to various modifications [Tan, et al., 2004]. For example, molecular
beacons have been commonly used for real-time monitoring of DNA or RNA
amplification during polymerase chain reaction (PCR) [Li and Tan, 2003]. Since the
initial development there have been various modifications of molecular-beacon sensors,
including miniaturized surface-immobilized hybridization assays and micro arrays [Vet, et
al., 2002; Broude, 2002; Lou and Tan, 2002, Epstein, et ai., 2003]. Molecular beacons

have also been used in monitoring genes in living cells.
FRET occurs between two fluorophores. Excitation energy is transferred from a
donor to an acceptor fluorophore. In the donor-acceptor pair, the emission wavelength of
the donor fluorophore must match the excitation wavelength of the acceptor molecule
[Didenko, 200 1]. As a result, the donor molecule fluorescence is quenched, and the
acceptor molecule becomes excited. It then loses energy via heat or the fluorescent
emission [Didenko, 2001]. The initial theory of FRET was developed by Theodor Forster
in 1948. The distance dependent FRET was experimentally confirmed by Stryer and
Haugland [1967] and Haugland, et al. [1969]. For FRET to occur, the distance between
the donor and the acceptor molecule must be within a distance of 0.5-10 nm, depending
on the specific donor-acceptor pair. The first biological applications of this phenomenon
started in the 1970s, dealing primarily with protein research [Didenko, 2001]. FRETbased DNA applications began to appear in the mid-1980s and 1990s and has gained
popularity because of the availability of the fluorescent protein [Piston, 2007; Miyawaki,
et al., 1997; Patterson, et al., 2001; Chalfie, et al., 1994]. The detection of FRET and its

disruption are both used in the assays. In FRET probes, the fluorophores are usually
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labeled onto two oligonucleotides separately, and when these two oligonucleotides form a
duplex, bringing the two fluorophores in close proximity, FRET occurs. Alternatively,
the hairpin configuration of the oligonucleotide labeled with the donor and acceptor
fluorophores can also result in FRET. DNA-based FRET probes are used in vitro and in

vivo in many applications monitoring various types of DNA and RNA reactions,
including peR, hybridization, ligation, cleavage, recombination, and synthesis. They are
also applied in sequencing, mutation detection, and as parts of biosensors to assess the
concentration of lead, DNNRNA and protein [Didenko, 2001; Piston, 2007].

B. METAL NANOPARTICLES AND FLUORESCENCE

With the advance in nanotechnology, the fluorescence alteration by metal
nanostructures has attracted much interest. These nanostructures are able to not only
quench the fluorescence, but also enhance the fluorescence intensity, providing the
sensing/imaging with the potential to increase the sensitivity and specificity.

1. Surface plasmon field of metal nanoparticles

Surface plasmon is coherent electron oscillation that exists at the metal-dielectric
material interface, such as a thin metal film, a small metal particle, or a sharp metal tip.
The existence of surface plasmon was first predicted in 1957 by Ritchie [1957]. The
localized surface plasmon polariton is collective electron-charge-oscillation in metallic
nanoentities, including nanoparticles, excited by light. The surface plasmon polariton can
propagate along the metal surface until the energy is lost either by the absorption by the
metal or by the radiation into the free-space. This propagating energy forms a surface
plasmon field near the metal surface. For metal nanoparticles, the surface plasmon is
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highly localized near the surface and rapidly decays from the particle surface into the
dielectric environment [GonzaIez-Diaz, et al., 2008]. The local surface plasmon exhibits
enhanced field strength at around the resonance wavelength and it is the highest at the
resonance wavelength. The resonance condition is determined by the absorption
spectroscopy and depends on the size and shape of the particle and dielectric properties of
both the metal and the surrounding material. For noble metals, such as gold and silver,
the resonance wavelength is in the visible light range [Evanoff and Chumanov, 2005;
Kreibig and Vollmer, 1995]. Therefore, gold and silver nanoparticles have been studied
extensively in their interaction with optical probes, such as fluorophores [Lakowicz,
2005; Zayats, et aI., 2005].
For bio-application, gold nanoparticles (GNPs) have been studied the most
because they have been well characterized, and they have little to no long-term toxicity or
other adverse effect in vivo [Connor, et aI., 2005; Shukla, et al., 2005]. Colloidal gold has
been safely used to treat rheumatoid arthritis for over 50 years [Merchant, 1998; Root, et
aI., 1954]. Recent study results indicate that the colloidal GNPs coated with a protective

layer of polyethylene glycol (PEG) exhibit excellent in vivo biodistribution and
pharmacokinetic properties after systemic application [James, et aI., 2007; Paciotti, et aI.,
2004; Paciotti, et aI., 2006]. Currently, a PEG coated GNP with targeting molecule is
already in a phase I clinical trial for advanced-staged cancer patients [Libutti.

el (II.,

2010].

2. Fluorescence alteration by gold nanoparticies

Since fluorescence is generated by the electrons excited by photonic energy, a
localized entity affecting the electron state of the fluorophore can change the fluorescence
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output. GNP forming surface plasmon upon receiving photonic energy can be, therefore,
good candidates for this purpose [Lakowicz, 2005; Zayats, et ai., 2005]. When a
fluorophore is placed very close to a GNP (e.g., within a few nanometers), the
fluorescence is usually quenched because the fluorophore donates the excited electrons to
the GNP, thus the electrons take the non-radiative pathway. However, as the distance
increases the electric field (plasmon field) near the GNP is still strong but the GNP is not
able to interact directly with the electrons of the fluorophore. Thus, the fluorescence can
be enhanced [Eustis and EI-Sayed, 2006].
The fluorescence quenching using GNPs has been studied by many researchers:
Ghosh, et ai. [2004] studied the effect of the GNP size on the fluorescence quenching;
Schneider, et ai. [2006] showed the degree of quenching as a function of the distance
between a GNP and a fluorophore; Dulkeith, et ai. [2002] observed a decrease in the
radiative decay of a fluorophore placed near a GNP; Kato and Caruso [2005] utilized the
quenching phenomenon in a competitive fluorescence immunoassay for biosensing and
imaging; Dubertret, et ai., [2001] used GNPs as fluorescence quenchers in DNA
molecular beacons; etc.
Utilizing GNPs for enhancing the fluorescence of fluorophores has also been
previously explored by several researchers. Nakamura et ai. [2005] studied the level of
the fluorescence enhancement with respect to the GNP size, for the fluorophore Rose
Bengal; Kuhn, et ai. [2006] and Anger, et ai. [2006] observed the change in the
fluorescence of Nile Blue with the distance from a GNP; Laurent and Asahi [2009]
obtained fluorescence enhancement of a film of N,N' -bis[2,5-di-tert-butylphenyl]3,4,9,1O-perylene dicarboximide by a single GNP.
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C. THEORY OF FLUORESCENCE ALTERATION BY METAL PARTICLES
Although numerous studies have demonstrated the ability of fluorescence
alteration by GNPs, to beneficially utilize fluorescence manipulation in designing
contrast agents, it is very important to thoroughly understand the correlation between the
manipulable parameters of the system and the fluorescence output. Theoretical analysis
using the mathematical model may be one of the most efficient ways for this purpose.

1. Mechanisms and Parameters

The mechanism of fluorescence alteration by metal nanoparticles has been studied
by many physicists as early as in 1980s. Gersten and Nitzan [1981], and Nitzan and Brus
[1981] studied the fluorescence from a single dye molecule adsorbed on a spherical metal
particle. They pointed out that the fluorescence change is a result of the competition
among the enhanced excitation, enhanced radiative and nonradiative decay rates near the
metal particle surface. They concluded that, for the dyes with low quantum yield, the
fluorescence is suppressed directly on the metal particle surface, but increased to a
maximum at a well-defined distance from the surface. These early theoretical
speculations were later verified by experiments with silver islands deposited on silicon
oxides [Wokaun, et al., 1983; Lakowics, 2005]. Anger, et al. [2006] and Kuhn, et al.
[2006] verified this theoretical prediction of fluorescence using a single-GNP and singledye system. This mechanism has been well accepted by many researchers [Wokaun, et
al., 1983; Anger, et aI., 2006; Farahani, et al., 2005; Bharadwaj and Novotny, 2007],

although these researchers may use different mathematical models for the fluorescence
alteration by metal nanoparticles.
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The main mechanism of fluorescence alteration and the parameters affecting the
fluorescence can be described as follows [Gersten and Nitzan, 1981; Bharadwaj and
Novotny, 2007]: When a fluorophore is placed in an electromagnetic field (plasmon
field) generated by a metal nanoparticle exposed to the incident light at a particular
wavelength, two main changes occur with the fluorescence output: (a) its excitation
decay rate (Fig. la) increases; (b) its the quantum yield (Fig. Ib) changes by the increase
in the radiative molecular decay rate, by the re-routing of the radiative decay to nonradiative decay, and by the intrinsic non-radiative decay rate (intrinsic quantum yield) of
the fluorophore.

-

Mechanisms

System Parameters Involved

(a)
Excitation decay
rate change

Fluorescence
change

(b)
Quantum yield
change

GNP size (1)

r--------Ex wavelength (2)
Radiative decay
rate change

GNP size (1)
Ex wavelength (2)

Absorption rate

Em wavelength (3)

Intrinsic nonradiative decay
rate

Intrinsic quantum yield (4)

Figure 1. Mechanisms (a and b) and the parameters (1-4) involved in the
fluorescence alteration by GNPs

The increase in the excitation decay rate is caused by the plasmon field generated
by the GNP upon receiving the photonic energy. The level of the increase is determined
by the plamson field strength, which depends on the GNP size and the wavelength of the
incident light (in a practical sense, the excitation wavelength of the fluorophore) and the
distance between the fluorophore and the GNP. The change in the quantum yield is
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affected by three different factors. (1) The increase in the radiative decay rate of a
fluorophore is caused by the plasmon field [Gersten and Nitzan, 1981; Bharadwaj and
Novotny, 2007]. (2) The non-radiative decay rate is induced by the GNP and it strongly
depends on the emission (Em) wavelength of the fluorophore. (3) The intrinsic quantum
yield of the fluorophore in the medium of interest also affects the results, especially when
the value is exceptionally small [Gersten and Nitzan, 1981; Nitzan and Brus, 1981;
Wokaun, etal., 1983].
The four main system parameters affecting the fluorescence change by a GNP are,
therefore, the GNP size, the Ex and Em wavelengths, and the intrinsic quantum yield of
the fluorophore (Fig. 1). In addition to these four, an important, manipulable parameter is
the distance between a fluorophore and a GNP, because the plasmon field strength decays
with the distance from the GNP. To achieve a desired fluorescence alteration by GNPs,
therefore, it is helpful to thoroughly understand how these five parameters affect the
fluorescence output.

2. Mathematical model for plasmon field strength near a GNP
(a) Plasmon field
The plasmon field strength around a metal nanoparticle has been frequently
analyzed by the Mie theory [Born and Wolf, 1999; Hartling, et al., 2007]. The Mie theory
is based on the scattering of electromagnetic radiation by spherical particles and it is an
analytical solution of the Maxwell equation [Mie, 1908]. In biomedical applications,
metal nanoparticles are usually coated with a polymer layer to stabilize the particle and
increase the hydrophicility. Therefore, the effect of the layer on the field distribution
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must be considered. Neeves and Birnboim [1989] extended the previous model for bare .
metal nanoparticle to the one for the field strength near a core-shell nanoparticles
dispersed in a dielectric medium. This particular model is limited to the dipolar
contribution. The particle concentration is to be sufficiently dilute so that the interparticle interaction may be ignored, and the intrinsic dielectric non-linearity is neglected
[Neeves and Bimboim, 1989]. The model uses spherical coordinate system (Fig. 2). The
GNP (radius, rl) is placed in the center of the coordinate (Fig. 2a) and it is coated with a
shell (thickness, r2-rl). The dielectric permittivities of the core, the shell and the medium
are c/ ,

£ 2'

and

direction, at {}

£ 3'

respectively (Fig. 2b). An incident light (g) is applied in the z

= o. The azimuthal symmetry ( dE/ d¢ = 0) is assumed.
z
p

Point of interest

y

x

iii . . - -

Incident Electric Field

(a)

(b)

Figure 2. (a) The coordinates used in the computation of the plasmon
field strength on and around a GNP and (b) a schematic diagram of a
GNP with polymer coating in a medium.

The plasmon field strength (E) at a position r in the medium can be then described
as in Eq (1).
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(1)

where

e and eo are the unit vectors in rand 8

, respectively, and

r

(2)

(3)
(4)

The factor P is the ratio of a shell volume to total particle volume. The field strength
inside the shell (E1ayer; in our case, biopolymer coating) is:

(5)

For a GNP,

£]

is wavelength dependent. It is available as experimental data

[Johnson and Christy, 1972], or it may be obtained by the Drude-Lorentz model (Eq. 6):
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where i denotes imaginary number;
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,

is the frequency of the incident light;

(6)

W o,

bound

electron resonant frequency; wp , plasma frequency; and
(7)
7:j and 7:b

are the free electron scattering and the bound electron decay time, respectively.

Vjis the Fermi velocity and

Lo,

the free electron scattering time in the bulk material. The
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dielectric function of a GNP by Drude-Lorentz model has been confirmed to agree with
the experimental data by Neeves and Birnboim [1989].

(b) Fluorescence change of a fluorophore near a GNP
The two approaches in developing the theoretical model for the fluorescence of a
fluorophore affected by a metal nanoparticle are the steady state approach and the
quantum mechanical approach. Gersten and Nitzan [1981] developed the models in both
way and their models were often used by others.

(b-i) Steady state model
This model is for a system with a single fluorophore and a single metal
nanoparticle. The relationship between an excited fluorophore and a metallic particle is
presented with the dipolar and higher order multipolar contributions. For the particles
with the size corresponding to the Rayleigh limit (dimensions s IJI0, A is the wavelength
of the incident light or fluorescence), only the dipolar part is relevant for fluorescence
radiation. Gersten and Nitzan pointed out that the fluorescence change (Y) of a
fluorophore near a metal nanostructure is a product of two factors: L( w exc ) ' the
amplification number of the local field, and Z( wf/u)' the partitioning of the excitation
energy into the various radiative and non-radiative decay channels, by the presence of the
particle.

y
where

=

W exc

(8)

IL( W exc )12 Z( wf/u)'

is the excitation frequency. L( W exc) can also be expressed as ElF: as used in

equation (1).
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Equation (8) was used later by many other researchers [Kummerlen, et ai., 1993;
Nakamura, et ai., 2005; Kuhn, et ai., 2006; Bharadwaj and Novotny, 2007; Hartling, et

ai., 2007]. Bharadwaj and Novotny [2007] expressed this model in a more explicate way:

Y:m = [Y:,c] [:],
Yem
Yexc
q

(9)

where Yem is the emission decay rate, Yexc is the excitation rate, and q is the quantum
yield, and the superscript ,0, denote the values without the particle. Following to the
Fermi's Golden Rule [Fermi 1950], the excitation decay rate below the optical energy
saturation can be expressed in terms of E2:

Y:xc
Yexc

= 1 Eo 12

(10)

E

The intrinsic quantum yield of the fluorophore (qO) is defined to be
o

qo =

Yr
00'
Yr + Ynr

where yOr and

Y~r

(11)

are the radiative decay rate and non-radiative decay rate of the

fluorophorewithout the particle, respectively. When the fluorophore is placed

In

a

plasmon field, both radiative decay rate and non-radiative dacay rate changed.
The expression of the radiative decay rate, Yr , is derived by computing the
radiative power induced by the particle using the polarizability of the particle [Gersten
and Nitzan, 1981; Bharadwaj and Novotny, 2007]. Fora spherical particle without
coating, in vacuum, with quasi-static polarizability, they found
(12)
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This expression for

y,/ y;

is identical with the

IE/ EOl2 for the particle in vacuum, at 8=0,

and with incident light frequency of WI.
The particle also changes the non-radiative decay rate of the fluorophore by
adding an additional non-radiative decay rate (y tlb.J This rate can be deduced from the
power that is radiated by the fluorophore and absorbed by the particle (for us, GNP).
Using the electrostatic image theory [Novotny and Hecht, 2006], the power emitted by
the fluorophore and absorbed by the particle inside a half-space can be calculated by
integrating the dissipated power density, and the energy transfer rate becomes

(13)

where

WI

is the emission light frequency, c is the speed of light and p = [Px,Py,Pz] is the

transition dipole moment. At 8=0,
(14)

The intrinsic non-radiative decay rate can be written as

y::r = y;. (1- qO ) / qO. This

accounts for nonradiative losses inside the fluorophore only, i.e., it is an intrinsic property
of the fluorophore. The quantum yield of a fluorophore affected by the particle then
becomes [Bharadwaj, et ai., 2007]
I

(l

Yr
lJ= f o
Y,lYr +Yab,/Yr +(1-q )/q
YT/

If)

00

(15)

In summary, for a selected fluorophore, when the particle size, the coating

material and the distance between a fluorophore and a particle are known, the
fluorescence change by the particle can be estimated using Eqs 1-15.
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Angers, et al. [2006] and Bharadwaj and Novotny [2007] have used this theory to
compute the fluorescence alteration of a fluorophore Nile Blue and a single GNP (60 nm).
Their theoretical results correlated well with the experimental results. Cheng, et aI., [2011]
used DNA strands of various lengths to control the distance between a fluorophore and a
GNP of various sizes, and their experimental results also matched well with the
theoretical prediction using the model.

(b-ii) Quantum mechanical model

Gersten and Nitzan [1981] have developed a quantum mechanical model that
considered the system with the molecular dipole and the particle's plasmons. The model
provides the Hamiltonian and the equations of motion for the system in the presence of
the incident radiation field. However, the model is limited to the case when the distance
between the fluorophore and the particle is greater than the radius of the particle [(rr 1»r 1]. Vukovic, et al. [2009] also developed a model using quantum mechanics. The

model considers the chemical structure of the fluorophore, instead of using a point-dipole
approximation, and is not limited to single particle, but can address a variable number of
particles.
The relative brightness,

qJRB

is determined by
(16)

where q is the quantume yield of the fl uorophore as described in Eq. (11), Afree is the
molecular absorption coefficient in the absence of the particle. The ratio AIAFee accounts
for the different population in the excited state induced by the particle on the molecular
absorption. This equation actually has the same physical meaning as in Eqs. (8) and (9).
While in computing radiative (Yr) and non-radiative decay rate (Ynr) and the absorption
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coefficient (A), the particle is considered as a continuous dielectric characterized by the
optical constants and the fluorescence is treated quantum-mechanically [Corni, et aI.,
2002; Andreussi, et ai., 2004]. The model belongs to a family of the polarizable
continuum model (PCM) [Tomasi, et ai., 2005]. The fluorophore is described by an
effective Hamiltonian. The electrostatic interaction energy between the molecular charge
density and the polarization of the particle is induced by the molecular charge density
itself. These charges are obtained by the boundary element method solution of the
integral equation formalism approach to the Poisson problem [Vukovic, et aI., 2009].
The absorption coefficient, A, is given by
(17)

where h is the Dirac constant,

n

is the refractive index of the medium, and

transition dipole between the ground state and the

Kth

"KO

is the

excited state, and it is directly

affected by the interaction with the particle (metal) and the solvent:
-mol

fL Ko

-met

-sol

= fL KO + fL KO + fL KO

(18)

'

-mol

-met

-sol

where fL KO is the molecular transition dipole, fL KO and fL KO are the transition dipole
effect of the particle and the solvent, respectively.
The radiative decay rate (yJ and non-radiative decay rate (Ynr) are
(19)
Ynr

= -2 Im( P ) ,

(20)

where P is the excitation energy.
Vokuvic, et ai. [2009] used this model (Eq. 16-20) to compute the fluorescence of
N,N'-dimethylperylene-3,4,9,1O-dicarboximide in combination with silver and gold
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nanoparticles, and the results account for continuous change from quenching to
enhancement. However, there have not been many experimental verifications of this
model.

D. NANOPARTICLES FOR BIOMEDICINE

In 1959, Richard Feynman introduced the concept of nanotechnology in his
pioneering lecture titled "There's plenty of room at the bottom" at the annual meeting of
the American Physical Society [Appenzeller, 1991]. However, nanotechnology has
become a rapidly growing field only in the recent decade. The term "nanotechnology"
varies greatly based on the specific definition that is used. The U.S. National Science
Foundation and the National Nanotechnology Initiative define the nanotechnology as
understanding and control of matter at dimensions of 1-100 nm, where unique
phenomena enable novel applications [Khademhosseini and Langer, 2006].

1. Advantages of nanoparticles for biomedical application

Nanotechnology is an emerging field that would potentially make a major impact
to human health [Khademhosseini and Langer, 2006]. Living organisms are built of cells
that are typically in the range of 10 !Am. However, the cell parts are much smaller and are
in the sub-micron size domain. The proteins are even smaller, with a typical size of 5 nm.
This size comparison reveals that using nanoparticles as probes would allow us to
understand the cellular machinery at a molecular level, without introducing too much
interference [Taton, 2002; Salata, 2004]. Understanding of biological processes on a
nanoscale level has been a strong force behind the development of nanotechnology
[Whitesides, 2003].
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The small size of nanoparticles makes them suitable for bio-tagging or labeling.
The surface of a nanoparticle can be conveniently used for a molecular assembly. The
molecules are usually one or more than one of the following: The small molecules that
make the particle biocompatible, antibodies/aptamers/peptide for biomolecule detection
or in vivo targeting, fluorophores for signaling, drugs for disease treatment, etc. Since a
particle can carry more than one function in a single entity, multifunctionality is a
fundamental characteristic of nanoparticles [Salata, 2004; Singh, et at., 2009]. Studies
have also shown that nanoparticles feature a longer circulation time in blood, higher
uptake rate by cells [Davis, 2008] and a high concentration of drug in/around them
[Ferrari, 2005]. In addition to these general advantages, many nano-materials exhibit
unique properties, e.g., optical, magnetic properties, etc., which can be beneficially
utilized for biomedicine.
These advantages and special properties of nanoparticles have made nanomedicine a booming research area, especially in cancer diagnosis and therapy. During the
past decades, advances in cancer biology have not been translated into medicine
appropriately, mainly due to the inability of administering contrast agents and therapeutic
moieties selectively to the desired targets [Langer and Tirrel, 2004; Ferrari, 2005].
Nanomaterials may be, therefore, excellent candidates for overcoming these issues.

2. Types of nanoparticles

Most of the nanoparticles currently being developed for medical use may be
classified into two: i.e., particles of organic molecules mainly and those with the
inorganic element, usually metals, as the core.

27

(a) Organic nanoparticles

Organic nanoparticles including liposomes, dendrimers, and other bio-polymers
are being developed for drug delivery to various human tumors, including breast cancer
[Park, 2002; Hofheinz, 2005]. The first nano-vehicle for drug delivery is liposome. As
other nanoparticles, liposomes feature longer circulation time especially when the surface
is modified with PEG. With the leaky nature of the cancer neovasculature, they may have
a significant selectivity in drug delivery to tumors [Papahadjopoulos, et aI., 1991; Oku
and Namba, 1994]. Liposome-encapsulated formulations of doxorubicin were approved
in the 1990s for the treatment of Kaposi's sarcoma, and are now used to treat breast and
refractory ovarian cancer. Liposomes continue to be refined and applied to more cancer
types [Langer and Tirrel, 2004; Allen, 2002; Park, 2002; Kircher, et al., 2003; Ferrari,
2005].
Dendrimers and various bio-degradable polymers, such as poly(lactic acid) (PLA),
poly (glycolic acid) (PGA), poly (lactic co-glycolic acid) (PLGA) and polyanhydride are
also being studied to encapsulate drugs. The particles can be designed to release drugs
through the bulk erosion, diffusion, or being triggered by the external environment, such
as changes in pH, light, temperature or by the presence of certain biomolecules
[Khademhosseini and Langer, 2006; Langer and Tirrel, 2004]. They can also be used to
encapsulate highly toxic, poorly soluble or relatively unstable drugs whose clinical use
was limited without using nano-capsules [Langer, 1998]. These particles may also
include disease-targeting molecules for targeted delivery.
In addition to the drug delivery, nanotechnology has contributed to advance in
medical techniques, such as implantable nanoporous membranes [Tao and Desai, 2003],
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controlled release biochips [Santini, et ai., 1999], and transdermal microneedle systems
[Prausnitz, et ai., 2004]. New organic nanoparticles are still being discovered and
characterized, providing potential future applications.

(b) Inorganic nanoparticies

Inorganic nanoparticles are usually a metal or metal compound possessmg
medically beneficial properties, including size-dependent physical properties, optical and
magnetic effects [Salata, 2004].

(b-i) Gold nanoparticies

Noble metal nanoparticles, such as gold and silver, possess umque optical
properties. In biosensing, for years, gold and silver nanoparticles have been used in
surface-enhanced Raman scattering (SERS). The sensitivity enhancement factor of SERS
is as high as 10 14 _10 15 , which improves the detection limit [Boisselier and Astruc, 2009].
GNPs are used to develop biosensors utilizing the surface plasmon peak shift by their
surface or environment change, such as the binding of analytes onto GNP surface
conjugated with the recognition molecule, the inter-particle distance changes when GNPs
bind to each other via the molecules conjugated on the surface [Jain, et aI., 2008].
For bioimaging, GNPs are also studied for many other imaging modalities: Large
GNPs (>20 nm) can be imaged using an optical microscope in the phase contrast or
differential interference contrast mode [Boisselier and Astruc, 2009]. Small GNPs absorb
light and generate heat which can be detected via the local variation of the refractive
index using Differential Interference Contrast (DIC) microscopy or via the heat-induced
liquid expansion using photoacoustic imaging [Boisselier and Astruc, 2009]. GNPs can

29

also be used in optical coherence tomography (OCT), which is an optical analogue to
ultrasound with a relatively good resolution (1-10 !lm) [Skala, et aI., 2008]. GNPs
generate an enhanced signal for the multi photon surface plasmon resonance (SPR)
microscopy when they are illuminated at their resonance frequency [Yelin, et aI., 2003].
They also generate better contrast in X-ray scattering than the organic contrast molecules,
providing high signal-to-noise ratio for the X-ray and X-ray computer tomography
[Hainfeld, 2006; Cai, et ai., 2007; Kim, et at., 2007]. GNPs are also studied to enhance
gamma radiation using neutron activation [Sperling, et at., 2008].
For medical therapies, GNPs are studied for optical cancer hyperthermia
(photothermal therapy) [Boisselier and Astruc, 2009]. GNPs have high absorption cross
sections requiring less irradiation energy and the irradiation via the SPR of GNPs
converts energy from light to heat fast [Hirsch, et ai., 2003; O'Neal, et aI., 2004; Loo, et

aI., 2005; Huang, et ai., 2006]. NIR is desired for its deep penetration into tissue and the
small GNPs (10-30 nm) forming larger clusters absorb NIR light (700-1000 nm) well
[Zharov, 2005]. Gold nanoshells and nanorods that absorb light in NIR are also
extensively studied for this purpose [Hirsch, et ai., 2003; Loo, et ai., 2005].
GNPs are typically synthesized by reduction of chloroauric acid [H(AuCI4)] using
citric acid. They are stabilized by citric acid, but not stable in solutions with a high ionic
strength. GNPs for biomedical uses require high stability in physiological conditions,
while maintaining their optical properties. Stability, from a biological point of view,
means good solubility and dispersivity in the physiological environment, as well as the
cellular or molecular interaction [Duchesne, et aI., 2008]. The solubility can be achieved
by coating the GNP surface with a stable and biocompatible hydrophilic shell.
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Shell materials that have been frequently used are the polymeric capping agents,
such as, amino- or mercapto-dextrans or polyethylene glycol (PEG) (Fig. 3a) and the
thiol ligands with hydrophilic end groups, which form a self-assembled monolayer
(SAM); (Fig. 3 b) [Duchesne, et al., 2008]. Compared to the arbitrary polymer coating,
the SAM provides important advantages. The thickness of the coating layer may be kept
minimal, which is particularly important for our study with spacers of a short length. It
avoids the steric hindrance of the GNP during penetrating into cells or synapses.

(a)

(b)

Figure 3. GNP stabilized with (a) large polyethylene glycol molecules and
(b) with small aliphatic-PEG molecules

A number of SAM ligand shells have been developed, and they usually follow a
basic design composed of a hydrophobic chain (aliphatic chain), allowing tight packing
of the monolayer, and a hydrophilic terminus to provide solubility in physiological
environments [Duchesne, et aI. , 2008 ; Pciotti, et aI. , 2006; James, et aI. , 2007]. The mostused materials for the hydrophilic terminus are PEGs, because PEG layer provides the
GNPs with excellent hydrophilicity to the particle, and it minimizes the adsorption of
particles to proteins [Ostuni, et aI. , 2001].
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(b-ii) Magnetic nanoparticie
Magnetic nanoparticles (MNP) have recently attracted attention because of their
ability of increasing contrast for MRI and cancer hyperthermia. Iron oxide nanoparticles
(Fe304, Fe203) are the most explored for these purposes. When the ferrite nanoparticles
become smaller than 128 nm they become superparamagnetic, which prevents selfagglomeration because they exhibit the magnetic property only when the magnetic field
is applied [Weissleder, et al., 1990]. They were found to have much greater magnetic
susceptibility than traditional MR contrast agents, such as gadolinium [Cuenca, et aI.,
2006]. They have rapid hepatic uptake after intravenous administration, which makes
them useful for the characterization of hepatic tumors [Ferrucci and Stark, 1990].
Ultrasmall-superparamagnetic iron oxide nanoparticles (SPIONs; 5-10 nm) may have
better tissue distribution, allowing uptake in lymph nodes and bone marrow [Weissleder,

et aI., 1990]. They have been used therefore, clinically in human for characterizing lymph
node status in patients with cancers [Cuenca, et aI., 2006].
MNPs can be heated in an alternating electro-magnetic (AEM) field, by hysteresis
loss, Neel relaxation, orland Brownian relaxation [Hergt, et aI., 1998]. Therefore, they
are extensively studied for localized cancer hyperthermia [Jin, et aI., 2006; Kumar and
Mohammad, 2011]. Compared to the traditional hyperthermia treatment, MNPs can be
targeted for the cancer by using the disease-specific binding agents, making the treatment
tumor.-specific. The AEM frequencies utilized are harmless to the body and generate heat
only in the tumor containing MNPs [Rand, et aI., 1985]. This hyperthermia method can
be combined with controlled delivery of drugs, utilizing heat-induced bond-breaking
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between drug and polymer on the MNP, heat-enhanced permeability of the drug from the
polymer to the tumor, etc. [Kumar and Mohammad, 2011].
Paramagnetic nanoparticles have also been used in concentrated drug delivery to
tumors [Cuenca, et ai., 2006]. Alexiou, et ai. [2000] used magnetic fields to concentrate
methotrexate-conjugated nanoparticles in tumor to focus greater amounts of the drug in
the desired areas, while being able to lower the systemic or intra-arterial concentration.
This drug delivery system was translated into a Phase I clinical trial and demonstrated
better patient tolerance of therapy with the successful localization of nanoparticles to the
tumors but with no magnetic field-associated toxicities [Lubbe, et ai., 1996].
Nanoparticles with a magnetic core, either of elementary Iron or Cobalt, with
nonreactive shell have been synthesized recently for biomedical research application
[Grass and Stark, 2006]. Magnetic CoPt nanoparticles and iron-oxide-based magnetic
materials have been used in clinical practice as contrast agents for MRI [Meng, et ai.,
2011].
MNP may also be coated with a gold layer to incorporate the optical properties of
gold and achieving multi-functions for disease diagnosis and treatment [Chen, et ai.,
2003].

In general, nanoparticles features numerous advantages that can be beneficially
applied to biomedicine. Although this study focuses only on the unique phenomenon of
fluorescence manipulation by GNP, the GNP can be a platform to incorporate many other
beneficial functions in the future.
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E. FLUORESCENCE ALTERATION BY GNP, PREVIOUSLY STUDIED BY
THE KANG GROUP

The Kang group has been studying the application of GNPs for fluorophoremediated biosensing and bioimaging since 2005. Hong and Kang [2006] applied GNPs to
a fiber-optic immuno-biosensing system to increase its sensitivity. The sensor performs a
fluorophore-mediated sandwich immunoassay on the sensor surface, and the fluorescence
intensity is correlated with the analyte concentration [Kang et a!., 1997; Spiker et a!.,
1998]. Fluorolink Cyanine 5 (Cy5, Ex/Em 647/679 nm) and Alexa Fluor 647 (AF647;
Ex/Em 649/666 nm) were used as the fluorophore. To adjust the distance between the
free GNP and fluorophores in solution, self-assembled monolayers (SAMs) at various
thicknesses were coated on the gold particle surface. The effect of GNP size and the
SAM thickness on fluorescence enhancement was studied. .
Hong and Kang [2006] also found that some solvents can enhance the
fluorescence of a fluorophore, by shifting the fluorophore excitation/emission
wavelengths [Buschmann, et a!., 2003], and/or by changing the trans-cis isomerization
direction [Aramendia, eta!., 1994; Scaffardi, eta!., 1997; Rodriguez, eta!., 1997], and/or
by shrinking proteins if fluorophores are tagged to them [Bonincontro et al., 1997;
Ruckebusch et a!., 1999]. They have found that I-butanol and ethanol gave high
enhancement without denaturing the antibodies immobilized on the sensor surface. To
maximize the enhancement effect, the two enhancers, the GNP-SAM and the solvent
were mixed to form GNP reagent (GNPR). Hong, et a!. [2006] and Wang, et al. [2008]
applied the GNPR in Alexa fluorophore (Alex-647) mediated four-cardiac marker
sensing system to be used for real-time diagnosis of acute myocardial infarction. By
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using GNPR, the size of the sensors was reduced from 3 cm to 1.5 nm, enabling a
portable, mini-sensing chip (2 x 2.5 cm), and this system can accurately quantify four
cardiac markers simultaneously at clinically significant concentration range within 15
min, requiring a plasma sample volume of only 200 [!l.
In biosensing the distance between the GNP and the fluorophore may not be
precisely controlled because only the minimum distance between these two may be
controlled by the thickness of the SAM. The distance may also be strongly affected by
the GNP concentration, because the reagents are confined in a small sensing channel
[Wang, et ai., 2008]. However, this problem may be resolved by testing the agent for the
controlled sensing protocal.
Unlike in the biosensing, for bioimaging in vivo, the fluorophore needs to be
physically linked to the GNP and the distance between the GNP and the fluorophore
needs to be well controlled. Kang, et al. [2011] have studied the fluorescence change of
an NIR fluorophore, Cypate, with changing the distance from a 10 nm GNP. The distance
was controlled by coating a polymer layer at known thickness on the GNP. Cypate was
placed on the outermost layer of the polymer coated GNPs, artificially separated from the
GNP at the distance of the polymer layer thickness, and its fluorescence levels were
observed.

The fluorescence of Cypate on the particle surface was quenched almost

completely and, at approximately 5 nm from the surface, it was enhanced -17 times.
Then the level went down thereafter.

This study experimentally suggested the

relationship between the level of Cypate fluorescence alteration and the distance from a
GNP.

35

To have a thorough understanding of fluorescence alteration by GNP, this
dissertation theoretically studies the fluorescence of various fluorophores affected by
GNPs. In addition, experimentally, a novel, highly specific and sensitive contrast agent
for bioimaging is developed utilizing fluorescence alteration by GNP.
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CHAPTER III
MATERIALS, INSTRUMENTS, AND METHODS

A. THEORETICAL STUDY
The fluorophores selected for our study are the ones frequently used in biomedical
studies and at various EmlEx wavelengths. They are Fluorescein isothiocyanate (FITC),
Alexa Fluor 532 (AF532), Cyanine 3 (Cy3), Alexa Fluor 647 (AF647), Alexa Fluor 700
(AF700) and Indocyanine Green (ICG). The fluorophores, their ExlEm peak wavelengths
and intrinsic quantum yield values are listed in Table 1.
Table 1. Fluorophores studied, and their excitation/emission peak
wavelengths and intrinsic quantum yields.
Fluorophore
FITC
AF532
Cy3
AF647
AF700
ICG (Cypate)

Excitation peak
wavelength (nm)
494
530
550
650
702
780

Emission peak
wavelength (nm)
521
555
570
665
723
830

qO
0.93
0.61
0.15
0.33
0.25
0.012

Solutions for the mathematical model were computed using Matlab R200Sa (The
Mathworks Inc., Natick, MA). The dielectric permittivity values used in the plasmon
field strength computation are: for GNPs, the experimental data by Johnson and Christy
[1972] were used; for the shell, value for polyethylene glycol (PEG), 2.S5
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t{"

was used,

where

Eo

is the dielectric constant of vacuum, 8.85 x 10- 12 C2/N m 2 • For the surrounding

medium, water, the

E3

value of 1.76

Eo

was used.

B. SYNTHESES OF SPACERS AND MODIFICATION OF CYPATE
In this section, the materials, instruments and methods of making the spacers.
SSP-Cy and m-Cypate are presented.
The molecular spacers tested for Cypate fluorescence alteration were synthesized
by the Nantz group at the University of Louisville or by the NeoGroup Inc. (Cambridge,
MA) through customized peptide synthesis, with our design. The detailed structures of
the spacers are listed in Table 2.

Table 2. Molecular spacers used for conjugating Cypate to GNPs.
Catagory
Short spacer

Structure

Abbreviation

SH-(CH 2h-Gly-Gly-Arg-Gly-Gly-Gly-NH 2

SSP

SH-(CH 2}z-Gly-Gly-Arg-Gly-Gly-Gly-ONH 2

nSSP
LSP

HS-(CH2)12-(OCH2CH2)4-0NH2
HS-(CH2)lr(OCH2CH2)6-0NH2
Long spacer

HS-(CH 2)12-(OCH 2CH 2)s-ONH 2
HS-(CH2)16-(OCH2CH2)4-0NH2
HS-(CH2)16-(OCH2CH2)6-0NH2

cyclo[DAP(Aoa)-PEG5-(8-aminooctanoic
ac id )-Cys-G ly -Arg-G ly-G ly -G ly] *
* The molecular structure of rDSP is shown in Fig. 33.

Dual spacer

Producer
The Nantz group

(CI2PEG4)

LSP
(CI2PEG6)
LSP
(C12PEG8)

The Nantz group

LSP
(C16PEG4)

LSP
(CI6PEG6)

rDSP

NeoGroup Inc.

To enable the oxime coupling of Cypate to the nSSP and LSPs, The Nantz group
added aldehyde groups to the Cypate (modified-Cypate; m-Cypate).
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B-1. MATERIALS

Polystyrene resin and amino acids used in the synthesis of short and long spacers
were purchased from Novabiochem (San Diego, CA). The coupling agents, 3(diethoxyphosphoryloxy )-1 ,2,3-benzotriazin-4(3H)-one (DEPBT), hydroxybenzotriazole
(HOBt), N,N-Diisopropylethylamine (DIPEA), CH 2Ch, trifluoroacetic acid

and

triethylsilane were obtained from Aldrich (St. Louis, MO). All other materials were
purchased from Sigma Aldrich (St. Louis, MO), unless otherwise specified.
Cypate (Cy) was produced and supplied by The Achilefu group at the Department
of Radiology, Washington University School of Medicine, St. Louis, MO [Achilefu, et

at., 2002; Ye, et at., 2003].

B-2. INSTRUMENTS

For purifying the spacers after each reaction silica gel flash column
chromatography (Teledyne ISCO; Lincoln, NE) was used. Solvent evaporation was done
using a bench top solvent purifier SPBT-1 (LC Technology Solutions, Inc.) Synthesized
SPs was analyzed by HPLC (Waters Corporation Delta 600 instrument; Waters corp.;
Milford, MA) and high-resolution mass spectrometry (HRMS; LTQ FT Ultra mass
spectrometer; Thermo Scientific; Waltham, MA) with TriVersa NanoMate system
chipbased infusion (Advion Biosciences, Inc.; Ithaca, NY).
The theoretical length estimations of the spacers and other molecules were done
using the computer software Hyperchem 7.5 (Hypercube Inc.; Gainesville, FL).
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B-3. METHODS

The methods described in this section are the revised version of the project report
from the Nantz group.
(a) Synthesis of the short spacers

The short spacer, HS-CH 2-CH 2-G-G-R-G-G-G-NH2 (SSP) was synthesized using
standard solid-phase peptide synthesis techniques [Merrifield, 1963]. For HS-CH2-CH2G-G-R-G-G-G-ONH2 (nSSP), the HS-CH2-CH2-G-G-R-G-G-NH2 was synthesized
following the same methods used for SSP. Then 100 mg of the resin loaded with it was
swelled using Dimethylformamide (DMF) over 30 mins, filtered, and then treated with
0.21

mmol

Fmoc-protected

aminooxyglycine,

0.21

mmol

DIC,

0.21

mmol

Hydroxybenzotriazole (HOBt) and 0.42 mmol Diisopropylethylamine (DIPEA) in 2 mL
of DMF. After shaking the mixture overnight, the resin was filtered and then thoroughly
washed with CH2Ch 7 times. The resin was dried under vacuum, swelled using
dimethylformamide, filtered, and then treated with 20% piperidine in 3 ml DMF at room
temperature for 40 mins. The piperidine washing process was repeated once. The resin
was filtered and washed successively with DMF for 3 times and with CH2Ch for 5 times,
and then dried under vacuum.

(b) Conjugation of Cypate to SSP

0.227 mmol Cypate was added to the HSCH2CH2NH-G-G-R-G-G-G-NH2-loaded
resin (65 mg, 0.045 mmol peptide) in DMF at room temperature. 0.227 mmol DEPBT,
0.227 mmol HOBt, and 0.45 mmol DIPEA were added as coupling agents. After shaking
the mixture overnight, the resin was filtered and thoroughly washed with CH2Ch 7 times.
The resin was then dried under vacuum. To the HS-CH2-CH2-NH-G-G-R-G-G-G-
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NHC(O)-Cypate resin prepared above (15 mg, 0.01 mmol) in 0.3 mL ofCH2Cb, 0.06 mL
of triethylsilane was added at room temperature. After shaking the mixture for 15 min,
0.04 mL of trifluoroacetic acid was added and the resin suspension was shaken for 1 hr,
allowed to stand for 1 hr, and then shaken for 3 hrs. The resin was filtered and the filtrate
was concentrated by rotary evaporation. The residue was washed with diethylether for 5
times and dried under vacuum to obtain the target cysteamine-hexapeptide-cypate (SSPCy) conjugate. The conjugates were characterized with HRMS (FrICR).

(c) Synthesis of long spacers
Scheme 1 illustrates the procedure for the synthesis of HS-(CH 2)12-(OCH2CH 2)sONH2, as an example of the synthesis of long spacers.

Br~OH

-

(1)
TrS

~
\-1..

n

OH

(5,6)

(2,3)

..

TrS

~

..

n

(4)

X

Scheme 1. Synthesis route of the spacers

The sequence number in the content before corresponds to the numbers in Scheme 1.
(1) 7.56 mmol Potassium carbonate was added to a solution of 3.78 mmol 12-bromo-

dodecanol in methanol, at room temperature. After stirring it for 5 minutes, 4.90
mmol triphenylmethanethiol (TrS) was added, and then the mixture was stirred
for 16 hours. It was then diluted with diethyl ether and neutralized with
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Na2HP04/NaH2P04 buffer. The buffer was removed, and the organic layer was
washed with NaCI brine 3 times. The aqueous layers were combined and
extracted with diethyl ether, dried over Na2S04 and concentrated by rotary
evaporation. The crude residue [TrS-(CH 2)I2-0H] was purified by flash
chromatography.
(2) 30 mL dry CH 2Ch was added to a N2 purged flask containing 1.95 mmol
TrS(CH2)120H and equal mole of sodium bicarbonate.
(3) 4.88 mmol carbon tetrabromide and 5.07 mmol triphenylphosphine in minimal
dry CH2Ch were added, and stirred for 12 hours. The resulting solution [TrS(CH2)12-Br] was washed, extracted, dried and purified as described in the step (1).
(4) 6.18 mmol tetra(ethylene glycol) in DMF was added to 12.17 mmol sodium
hydride in DMF, at ODC under N 2. After 5 minutes, 1.03 mmol TrS(CH2)12Br in
DMF was added, and then allowed to reach room temperature and stirred under
N2 for 72 hours. The product [TrS-(CH2)12-(OCH2CH2)s-OH] was then washed,
extracted, dried and purified.
(5) 0.414 mmol N-hydroxyphthalimide and the same mole of triphenylphosphine
were added to 0.345 mmol TrS-(CH2)12-(OCH2CH2)s-OH in dry THF, under N2 at
ODC. Then 0.414 mmol diisopropyl azodicarboxylate was added dropwise. The

solution was warmed to room temperature and stirred overnight. The mixture was
concentrated by rotary evaporation, and washed, extracted, dried and purified
[TrS( CH2) 12-(OCH2CH2)s-ONPhth].
(6) 3.35 mmol hydrazine monohydrate was added to a solution of 0.168 mmol
TrS(CH2)120PEGsONPhth in CH2Ch, at room temperature, and the mixture was
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stirred for 3 hours. The product [TrS(CH2)12-(OCH2CH2)g-ONH2J was dried by
rotary evaporation and purified by flash chromatography.
(7) Excessive amount of trifluoroacetic acid and 0.073 mmol triethylsilane were

added to a solution of 0.123 mmol TrS(CH2)120PEGsONH2 in CH2Ch, at room
temperature and the mixture was stirred for 3 hours under N2. The product [HS(CH2)12-(OCH 2CH2)s-ONH2J was dried by rotary evaporation and vacuum
pumping, and then purified by flash chromatography.
Other spacers, HS-(CH2)n-PEGm-ONH2 for n=12 and 16, and m=4 and 6, were
synthesized following the same procedure. Each product was analyzed and confirmed
by HPLC and HRMS.

(d) Modification of Cypate

In this reaction, (C 2HsOhCH(CH2hNH 2 was conjugated to the two -COOH
groups of Cypate via the amine-carboxylic acid reaction, and the -CH(OC2HSh group
was then modified to -CHO.
(1) 0.48 mmol amino acetal (C 2HsOhCH(CH2hNH 2 was added to a mixture of 0.12

mmol Cypate, 0.48 mmol HOBt, and 0.48 mmol EDC in 2 mL dry DMF, at room
temperature, and the mixture was stirred overnight in dark, at room temperature.
(2) The step (1) was stopped by adding water, and the product [Cypate conjugated
with two molecules of (C2HsOhCH(CH2)3NH2J was extracted using CH2Ch. The
organic layer was washed with brine and then dried with Na2S04. The solvents
were removed by rotary evaporation and the residue was purified by column
chromatography (Si0 2, eluting with a gradient of 1-7% methanol in CH2Ch).
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(3) The product was hydrolyzed by dissolving it at 1.6 mg/ml in 30% aqueous acetic
acid, with stirring for 3.5 h at room temperature. The solvent was then removed
under vacuum to obtain aldehyde-Cypate (modified Cypate; mCy) as a green
solid.

C. CONJUGATION OF CYPATE TO GNP
C-l. MATERIALS
Gold nanoparticles (GNPs; 5, 10, and 15 nm according to the manufacture's
information; 3.7, 8.0 and 16.4 nm by our measurement) stabilized with citric acid and
tannic acid in aqueous solution were purchased from Ted Pella (Redding, CA).
The GNP coating material (I-Mercapto-ll-undecyl) tetra( ethylene glycol) [HS(CH2)w(CH2CH20h; MW, 380.58; sPEG] was from Asemblon (Redmond, W A) or
ProChimia Surfaces (Ul. Zacisze, Poland).
Urokinase-type plasminogen activator (uPA) was purchased from Innovative
Research (Novi, MI).
Pure argon was provided by Welders Supply (Louisville, KY) to blow-dry the
substrate; ethanol, dimethyl sulfoxide (DMSO) and all other chemicals were from SigmaAldrich, unless otherwise specified.

C-2. INSTRUMENTS
For GNP purification after conjugation, dialysis was done with Slide-A-Lyzer
Dialysis Cassettes (20K MW Cut-Off; Thermo Scientific; Rockford, IL). Centrifugation
was done using Eppendorf 5415 R Centrifuge (Eppendorf AG; Hamburg, Germany). A
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sonicator (Sonic Dismembrator; Fisher Scientific; Chicago, IL) was used to disperse
GNPs pellet in solutions after centrifugation.
For characterizating various GNP products, absorption spectra were used
(Beckman DU520 spectrometer; Beckman Instruments, Inc.; Fullerton, CA). The size of
GNPs before and after the surface modification was measured by a dynamic light
scattering (DLS) particle size analyzer (90PlusIBI-MAS; Brookhaven Instruments Co.;
Holtsville, NY) and a transmission electron microscope (TEM; Tecnai™ HR FEG-TEM;
FEI co.; Hillsboro, Oregon).
Fluorescence was measured by the Spectra Gemini XPS fluorometer (Molecular
Devices Corp.; Sunnyvale, CA) in the 96-well Uniplate (Whatman; Florham Park, NJ) at
the excitation and emission wavelengths of 780 and 830 nm, respectively.

C-3. METHODS
(a) Handling of thiolated materials:

The GNP surface coating materials (sPEG) and all spacers (SSP-Cy, nSSP, LSPs,
and rDSP) reacting to GNPs contain a thiol ending, which can be oxidized easily by
oxygen in the air. Therefore, special care is required in handling these spacers. The
spacers were received in a solid form at room temperature. To dissolve the spacers
ethanol was first purged with argon. The spacers were dissolved at a concentration of -5
mg, and the solution was divided into small aliquots, sealed in containers under argon,
and kept at -70°C for a short-term « 2 month). For a long-term storage, the spacer was
blow-dried with argon to form a solid and the container was sealed under argon, and kept
at -70°C.
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Pure sPEG is solid at 4°C and becomes liquid at room temperature. At room
temperature it is made into small aliquots and then kept under argon, at 4°C as a solid as
suggested by the manufacture. Before each use, sPEG was warmed to room temperature
and 2 !!L of sPEG was taken and dissolved in 500 !!L ethanol, forming stock solution at
3.4 mglmL (9390 !!M).

(b) GNP surface modification and Cypate conjugation
(b-i) Conjugation of SSP-Cy to GNP
SSP-Cy and sPEG were conjugated to GNP following the procedure described
below:
(1) SSP-Cy and sPEG were mixed at a molar ratio of 1:4 and diluted in ethanol in a
volume equal to the volume of the GNP solution to be added, to result in a 1: 1
(volume ratio) ethanol and water mixture.
(2) The colloidal GNP solution was added to the SSP/sPEG mixture and the mixture
was stirred for 4 hrs at room temperature. According to Duchesne, et al. [2002], a
tightly packed, mixed monolayer of sPEG and peptide on the GNP surface
corresponds to 3.6 molecules/nm2-GNP surface area. Here, the amount of SSP-Cy
and sPEG was at 60 molecules/nm2-GNP surface area (excess by 15 times).
(3) After the reaction, the solution was placed in a dialysis cassette and the cassette
was placed in 2 L of de-ionized (D!) water in dark with stirring overnight.
(4) The dialyzed sample was then centrifuged at 13000 RPM for 60 min. The pellet
was re-dispersed in 1 mL of D! water and sonicated for 5 minutes.
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(5) The GNP and Cypate in the solution were quantified by their respective
absorption peaks (520 and 780 nm, respectively).

(b-ii) Conjugation of nSSP to GNP! Conjugation of mCy to nSSP on GNP
nSSP and sPEG were first reacted onto GNP and purified, and then m-Cypate was
reacted to GNP-nSSP:

(1) nSSP and sPEG were mixed at a ratio of 1:4 and diluted in ethanol by the same
method described in step (1-3) of (b-i) above.
(2) The GNP was quantified by the light absorption at 520 nm.
(3) mCy was dissolved in ethanol at 2.5 mM; a blocking agent, Me3N+-(CH2h-ONH2
(BLK) was added to mCy solution at a 1: 1 molar ratio and reacted in dark, at
room temperature, overnight. Addition of BLK is to block one of the two reactive
-CHO groups of mCy, and increases the hydrophilicity of mCy.
(4) mCy-BLK was added to the solution from step (2) at 0.3 molecule/nm2-GNP
surface and reacted with stirring, for 4 hrs, in dark, at room temperature.
(5) The solution from step (4) was dialyzed using the cassette in 2 L of DI water with
stirring, in dark, overnight.
(6) The dialyzed sample was then centrifuged at 13000 RPM for 60 min. The pellet
was re-dispersed in 1 mL of DI water and sonicated for 5 minutes.
(7) The GNP and m-Cypate in the solution were quantified spectroscopically.
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(b-iii) Conjugation of m-Cypate to GNP via long spacers (LSP)
LSP and sPEG were first reacted onto GNP and purified, and then m-Cypate was

reacted to GNP-LSP.
(1) Colloidal GNP solution was concentrated -10 times by centrifugation at 13,000

RPM for 60 mins;
(2) The GNP concentration was determined by the absorption at 520 nm;
(3) To avoid aggregation of the GNP and crowding of mCy on the GNP surface, LSP
and sPEG were mixed at a molar ratio of 1:9, and the mixture with GNPs in
water, for 4 hrs at room temperature.

For the amount of LSP/sPEG, 60

molecule/nm2 -GNP surface area (excess by -15 times) was used;
(4) The purification of GNP-sPEGILSP, preparation of mCy-BLK, the conjugation of
mCy-BLK to GNP-sPEGILSP, and the purification and quantification of the final
product were done by the same way as described in section (b-ii).

(b-iv) Conjugation of rDSP to GNP and the conjugation of mCy to GNP-rDSP
rDSP and sPEG were mixed at 1:9 and diluted in ethanol at the same volume of

the GNP solution to be added; the rest of the steps were the same as steps (2-8) in section
(b-ii).

D. CELL STUDIES
D-l. MATERIALS
The human breast cancer cell lines, MDA-MB-231 and MCF-7, were purchased
from American Type Culture Collection (Manassas, VA). Dulbecco's Modified Eagle
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Medium (DMEM), Penicillin and Streptomycin were purchased through Invitrogen
(Carlsbad. CA).
Enzyme-linked immunosorbent assay (ELISA) kit for uPA was purchased from
Innovative Research (Novi, MI).

D-2. INSTRUMENTS
For the cell studies performed in the Achilefu group, the cells were plated on LabTek slides (BD Biosciences, Franklin Lakes, NJ). The fluorescence of media was
measured in a Pearl Imager (LI-COR, Lincoln, NE). Fluorescence of cells was visualized
with an Olympus FVlOOO confocal microscope (Olympus America Inc.; Center Valley,
PA) using a 20X water immersion objective, and fluorescence intensity was quantified
with a built-in photon counter. Before any GNP product is applied on the cell culture they
were sonicated using a sonicator (Sonic Dismembrator; Fisher Science, Chicago, IL) to
avoid any aggregation.
For the ELISA of uPA, to mix the reagents in a 96-well plate, the Titer Plate
Shaker was used (Millipore; Billerica, MA). The fluorescence was measured using a
Spectra Gemini XPS fluorometer (Molecular Devices Corp.; Sunnyvale, CA) in the 96well Uniplate (Whatman; Florham Park, NJ).

D-3. METHODS
(a) Quantification of uP A in cell media by ELISA
MDA-MB-231 and MCF-7 cells were plated at the density of 2500 cells/well (+/1% error in pi petting) in serum-free DMEM Media (150 jlLlwell), in a 96-well plate in
the Bates laboratory. For MCF-7 cells, 0.01 % Insulin was added.
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The plate was incubated in CO 2 incubator at 37°C. After 8 or 32 hrs of
incubation, 600 flL of the media sample was collected from both cell lines and frozen at 70°C immediately. The frozen media was thawed prior to the assay. To remove cells in
the media, the samples were centrifuged at 13 ,000 rmp for 10 min and the supernatants
were collected. The ELISA was performed as described below:
(I) uPA standards

of0.1~50

ng/ml was prepared in dilution buffer with BSA;

(2) The 96-well plate (8x12 removable strips) provided in the ELISA kit had already
been coated with capture antibody, and blocked and dried. 100 flL of the standard
and unknown samples were then added to each well, in duplicates, and the plate
was shaken at 300 rpm for 30 min;
(3) Blocking buffer (3% BSA in TBS buffer) was used to dissolve primary antibody.
100 flL of the primary antibody solution was added to each well and the plate was
shaken at 300 rpm for 30 min;
(4) The wells were washed with 300 flL washing buffer 3 times and removed.
Remaining washing buffer was removed by gently tapping plate on paper towel;
(5) 2 flL secondary antibody was diluted in 10 mL blocking buffer, and 100 flL was
added to each well. The plate was shaken at 300 rpm for 30 mins and washed with
washing buffer 3 times;
(6) 100 flL substrate was added to each well and the plate was shaken for 10 mins.
The reaction was then stopped by adding 50 flL of IN H2S04 stop solution to each
well;
(7) The absorbance at 450 nm was immediately read by Spectra Gemini XPS
fluorometer. The amount of uPA was quantified.
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(b) Cell studies with GNP-SSP-Cy
Cell study with GNP-SSP-Cy was performed at the Achilefu laboratory,
Washington University, St. Louis, MO. MDA-MB-231 and MCF-7 cells were plated on
Lab-Tek slides separately, at 3000 cells/well. The plates were incubated in serum-free
DMEM with 100 units/mL Penicillin and 100 units/mL Streptomycin (for MCF-7 cells
0.01 % Insulin is added), in C02 incubator at 37°C overnight. The experiment with GNPSSP-Cy was done as follows:
(1) GNP-SSP-Cy was sonicated for 5 min to avoid any aggregation.

(2) GNP-SSP-Cy was added to the well containing the cells, at the Cypate
concentration 10 pM, and incubated for 2 hrs.
(3) After incubation, the media in the well was pi petted out and put in a 96-well black
plate, and the fluorescence was measured by a Pearl Imager.

(c) Cell studies with GNP-LSP-mCy
Cell study with GNP-LSP-Cy was performed at the Achilefu laboratory. The cell
preparation was done the same as in (b). Then,
(1) GNP-LSP-mCy was sonicated for 5 min to avoid any aggregation; mCy-BLK or

GNP-LSP-mCy was added to the wells at the mCy concentration of 340 nM (for
GNP-LSP-mCy the GNP concentration was 10 nM);
(2) At 1, 3 and 24 hrs, the slides were removed from the wells and the cells were
imaged by NIR fluorescence confocal microscope.
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CHAPTER IV
RESULTS AND DISCUSSIONS

A. THEORETICAL ANALYSIS OF FLUORESCENCE ALTERATION BY GNP
As described in the theory section (Chapter II), the fluorescence alteration by
GNPs is affected by the GNP size, ExlEm wavelengths and intrinsic quantum yield of the
fluorophore, and the distance between the GNP and the fluorophore (Fig. 1). Once the
fluorophore is selected, in a practical sense, the wavelengths of the ExlEm light and the
quantum yield are fixed. The GNP size and the distance between the fluorophore and the
GNP are, therefore, the two parameters that can be manipulated. In this section, the effect
of each parameter on the fluorescence alteration was analyzed for the fluorophores with
various ExlEm wavelengths (490-830 nm) and intrinsic quantum yields (0.012-0.93),
which are frequently used in biosensinglimaging applications. Table 1 in Chapter III lists
the fluorophores (FITC, AF532, Cy3, AF647, AF700 and ICG) and their properties.
The mathematical model we are using is based on the interaction between a single
fluorophore and a single GNP, with no inter-particle interaction (Chapter II, Part C,
Theory). The system is symmetric in the azimuthal axis (dE / dfjJ = 0) and the light is
applied in the z direction (e

=

0). In our study, the following additional assumptions were

made:
(1) The fluorophore is placed at

e = 0 (along the z axis).
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(2) For each fluorophore, the excitation and emission are only at their peak wavelength
values.
(3) The fluorophore and GNP are placed in water.

1. Excitation Rate and System Parameters

(a) GNP size and incident light wavelength
The GNP size for in vivo application is desired to be in the range of 10-100 nm,
because this range provides a long circulation time in blood and an effective cell-uptake
rate [Davis, 2008]. The size includes the thickness of particle surface modification, such
as coating of polymers and/or other biomolecules conjugated on the GNP surface. The
core GNP size should be, therefore, smaller than the entire particle size. Based on these
conditions, the maximum GNP core size studied was 50 nm. For the distance between a
fluorophore and a GNP (i.e., the spacer length), a range of 0-10 nm was chosen because
this range provides a plasmon field strength sufficient for affecting the electron status of
the fluorophore. It is also a range for a linear bio-spacer to maintain its length reasonably
well. When a fluorophore is selected, the incident light wavelength to be used becomes
the excitation peak wavelength of the fluorophore. Figure 4 shows the enhancement of
the excitation decay rate (excitation rate) by a bare GNP of sizes 10, 30 and 50 nm for the
selected fluorophores at their respective excitation wavelengths, with the distance from
the GNP surface.
For all three GNP sizes, on the GNP surface the excitation rates of a fluorophore
are the same and they are the highest. The rates decrease rapidly with the distance and for
smaller GNPs, the decrease is faster. Therefore, at the same distance from the GNP, the
enhancement in excitation rate is greater for a bigger GNP.
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Figure 4. The enhancement in the
excitation decay rates of fluorophores
by their respective Ex wavelengths,
with respect to the distance from the
surface of a (a) 10 nm (b) 30 nm and
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In terms of the fluorophores (i.e., the wavelength of the incident light), AF532
(Ex 530 nm) shows the highest enhancement (36 times on the surface). Its wavelength is
slightly red-shifted from the plasmon resonance peak of GNP (520 nm). Hearting's
analysis [2007] studied that, in a medium with a relative dielectric permittivity greater
than 1 (The dielectric permittivity in our system is 1.76), the highest enhancement occurs
at a wavelength slightly red-shifted from the resonance peak. The level for Cy3 (Ex 550
nm) is only slightly lower. AF700 (Ex 702 nm) and ICG (Ex 780 nm) show lower
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enhancement (12 times on the surface). The lowest enhancement is for FITC, whose
excitation peak is at 494 nm, shorter than the GNP resonance wavelength.

(b) Effect of coating material on GNP
The plasmon field distribution is also affected by the materials coated on the GNP
surface. For biomedical applications, GNPs are usually coated with a biocompatible and
hydrophilic polymer to stabilize GNPs in water-based biological media. The coating also
prevents protein adsorption on the GNPs. One of the most commonly used polymers is
PEG. Figure 5 illustrates the plasmon field strength distributions, on and around a 10 nm
GNP coated with PEG at a thickness of 1, 2 and 3 nm, when the incident light at 780 nm
is applied. 780 nm is the excitation wavelength peak of ICG , and it is used as an example
because an ICG derivative is used in our experimental studies .
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Figure 5. Plasmon field distributions computed on/around a 10 nm GNP
coated with PEG, at a thickness of 0, 1, 2, or 3 nm, when the incident light
at 780 nm is applied.
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For all three cases, the field strength inside the PEG layer is approximately 15%
lower than that without the layer (Fig. 5). Therefore if the fluorophore is to be placed
inside the polymer, then the reduction of the field strength should be considered.
Immediately outside the layer, the field strength is slightly higher than that without the
layer. As the distance increase, the strength becomes very close to the one without it. It
should be noted that this trend is for the coating with dielectric materials. If the coating
material is metal, the plasmon field may be even enhanced instead of being reduced.

2. Quantum Yield Affected by Various Parameters

The change in the quantum yield of a fluorophore by a GNP is the combined
effect of the plasmon field strength on the radiative decay rate (y,) and the absorption
( Yah,) of emitted fluorescence by GNPs, and the intrinsic quantum yield of the

fluorophore, as shown in Eq. 15.

(a) Radiative decay rate

Since the radiative decay (y)y;') for the spherical particles may be assumed to be
the same as

Yex)r::" , it

is higher for the bigger GNP and is the highest for the

fluorophores with Ex wavelength slightly red-shifted from the GNP resonance peak.

(b) Absorption

The energy of the fluorophore absorbed by the GNP (Yabs) is determined mainly
by the Em wavelength of a fluorophore. Because the energy is absorbed by the GNPs, it
is usually the highest at the resonance peak wavelength of GNPs. Figure 6 shows the
absorption rates by a 30 nm GNP for the fluorophores with respect to the distance. The y-
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axis values are presented in a logarithmic scale due to the wide range of the number
within the distance. For all fluorophores, on the GNP surface the absorption is extremely
high (10 7 -10 8) , and it decreases rapidly with the distance. FITC (Em 521 nm) shows the
highest absorption (~ 1 08) , and remains very high over the distance studied. For the
fluorophores with emission wavelength away from the resonance peak, the absorption
rates are lower than that of FITC. For AF647, AF700 and ICG, the absorptions are the
lowest.
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Figure 6. Absorption rate ( Yobs / Y; ) of various fluorophores by a 30 nm
GNP, with respect to the distance from the GNP surface

(c) Intrinsic quantum yield

The effect of the intrinsic quantum yield (qO) on the fluorescence may be
understood better when we write Eq. 3 in the following format:

q
Yr /r;
qO= qO (y,/y~ +Yabj y; -1)+1

(21)
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For the fluorophore with high intrinsic quantum yield

(~1),

q/qO is mainly

determined by the value of1/(1+YabslYr)' For a fluorophore with very low qO (~0.01)
such as ICG, the value is larger. It also means that the fluorescence of those fluorophores
have more tendency to be enhanced.
Table 3 summarizes values of the first and the second term of the denominator of
Eq. 21 at 0.1 nm (close), 5 nm (middle) and 10 nm (far) from a 30 nm GNP surface and,
the third term for the fluorophores.

Table 3. Normalized radiative decay rate and absorption rate at 0.1, 5 and
10 nm from a 30 nm GNP surface, and (l_qO)/qO of the fluorophores.
0.1 om from GNP
surface

10 om from GNP
surface

Yr! Yr

Yall ..! Yr

Yr/ Yr

..
Yah,! y,

10.1
32.4
31.6
15.4
13.2
11.6

9. 0x10 6
4. 1x10 6
3. 0x10 6

3.4
9.2
9.4
5.4
4.8
4.4

543.6
244.5
180.0
40.0
32.7
33.0

Fluorophores

FITC
AF532
Cy3
AF647
AF700
ICG

5 om from GNP
surface

;

!

0

0

0.66x10 6
0.54x10 6
0.55x10 6

j

;

()

!

()

0

I' r;/1'''r

Ya"';Y r

1.9
3.9
4.1
2.8
2.6
2.4

72.1
32.4
23.9
5.3
4.3
4.4

()

(1- q )/q

0.1
0.6
5.7
2
3
82.3

When these three terms are compared, near the surface of the GNP (0.1 nm), the
f

0

absorption term Yah.,/ Yr dominates for all the fluorophores. As the distance from the GNP
;

0

;

0

,:

a

increases, both Yr I Yr and I'ab.\! Yr decrease, while Yah.,! Yr decreases much faster. At 5 nm
from the GNP surface, the Yah) 1':' values for the fluorophores with the emission
wavelengths close to the GNP resonance peak (FITC, AF532, and Cy3) are still much
higher than 1''/1';' or (l-q")lq". Therefore, the fluorescence tends to be still quenched.
For the fluorophores whose Em peaks are away from the GNP resonance wavelength
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(AF647, AF700, and ICG), at 5 run, their Yab) Y~ values decrease to the magnitude
comparable to Y'/ Y; and (l - qO) I qfl , and their quenching effect dominates no longer. At
10 run,

Y'/Y; decreases up to 1 /3~ 112 of the value at 5 run away, while Yabs/r; decreases

to ~ 1/8 of its value at 5 run.
Figure 7a illustrates the quantum yield (q/qO) for the fluorophores near a 30 run
GNP. ICG is discussed separately (Fig. 7b) because it has an unusually low quantum
yield (0.012). For all fluorophore, the q/qOvalues are the lowest at the GNP surface and
increase with the distance. For FITC, AF532 and Cy3, the values are extremely low even
at 10 run away from GNP surface due to their large

Yabsiy; values. AF700

q/qOvalues than other fluorophores because of its smaller

has greater

YObJy; and qOvalues.

When it

is 10 run away from the GNP surface q/qObecomes greater than 1.
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Figure 7. Theoretically computed quantum yield of (a) various
fluorophores (b) ICG with respect to the distance from a 30 run GNP

For ICG (Fig. 7b), the resulting quantum yield with respect to the distance from
the GNP shows a unique profile. At the distance less than 1 run, the q/qOis very low. It
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becomes greater than 1 when the distance is greater than 2 nm. It reaches the greatest (3.4
times) at 4.2 nm, and then slowly goes down toward 1. Therefore within the distance of 5
nm, the q/qO value changes from the minimum (on the surface) to the maximum (at 4.2
nm).

3. Resulting Fluorescence Output
The fluorescence output affected by a GNP is the combination of the
enhancement in excitation decay rate and the change in quantum yield (Eq. 9). Figure 8
shows the fluorescence output of the fluorophores, by a (a) 10 nm, (b) 30 nm, and (c) 50
nm GNP. Among the fluorophores studied, ICG shows a unique response to the plasmon
field generated by the GNP due to its NIR Ex/Em wavelengths and extremely low
intrinsic quantum yield. Therefore, the fluorescence output for ICG will be analyzed
separately. For all fluorophores, strong quenching occurs at the GNP surface. FITC
shows almost complete quenching (>99%) throughout the distance studied, for all three
GNP sizes. It is mainly because its emission wavelength (521 nm) is close to the plasmon
resonance peak of GNP and the energy absorption by GNP is very high. FITC is,
therefore, a good candidate for the fluorescence quenching, but not for the enhancement.
With a 10 nm GNP (Fig. 8a), for all fluorophores, the fluorescence is quenched
within 10 nm from the GNP surface. Therefore, 10 nm GNP may be a good candidate for
conditional fluorescing, such as molecular beacon, for these fluorophores.
As the GNP size increases, the level of fluorescence becomes higher for all
fluorophores. For a 30 nm GNP, the fluorescence levels of Cy3, AF647 and AF700 are
quenched within 2 nm from the GNP surface, and start to get enhanced when the distance
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is greater than 3 nm. When the distance becomes approximately 9 nm, the enhancement
becomes 2.5-4 times and afterwards, slowly decreases.
For a 50 nm GNP, the distance for fluorescence quenching is even shorter and the
fluorescence enhancement is greater and starts at a shorter distance than for the 30 nm
GNP. The enhancement for Cy3 , AF647 and AF700 is up to 5-10 times. Even the
fluorescence of AF532 gets enhanced at a distance of 4.5 nm. The distance for the
maximal enhancement is longer for the larger GNPs.
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The theoretical study results for fluorescence manipulation using GNPs may be
summarized as follows:
For fluorescence quenching:

(1) The fluorophores with the Em wavelength near the GNP plasmon resonance peak
are good candidates.
(2) On the GNP surface, the fluorescence of fluorophores is always quenched.
(3) For the fluorophores with Em wavelengths significantly longer than the GNP
resonance peak, e.g., far-red or NIR fluorophores, the distance between the GNP
and the fluorophore needs to be shorter to achieve the same level of quenching.
(4) Bigger GNPs require shorter distance from the fluorophore to quench the
fluorescence.

For fluorescence enhancement:
(l) Only the fluorophores with Ex/Em wavelengths longer than the resonance peak

wavelength of GNP, may be effectively used for fluorescence enhancement.
(2) The GNP size needs to be sufficiently large to generate a plasmon field strong
enough to enhance fluorescence. In general, bigger GNPs provide greater
fluorescence enhancement.
(3) The fluorophores with a lower quantum yield have more potential for the
fluorescence enhancement.
(4) To obtain the maximal fluorescence enhancement, the distance between a
fluorophore and a GNP needs to be accurately selected.
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4. leG Fluorescence Alteration by GNPs
The fluorescence of ICG altered by a GNP was studied more in details here
because ICG is the basis of Cypate, the fluorophore used in our experimental studies, and
because it has Ex/Em wavelength in NIR and a very low quantum yield (Table 1).
Figure 9 shows the enhancement of the excitation decay rate by ICG excitation
wavelength (780 nm) by GNPs at the size range of our interest, with the distance from the
GNP surface. As for other fluorophores, larger GNPs provide greater enhancement,
although the values are lower
resonance wavelengths

(~ 12)

than those for the fluorophores close to the GNP

(~36) .
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Figure 9. The enhancement in the excitation decay rates of ICG (Ex
wavelength 780 nm) by GNPs at various sizes.

For the quantum yield of ICG, the effects of the absorption rate and the intrinsic
quantum yield were analyzed in detail because of the uniqueness of ICG in these two
aspects. The absorption rate (Yab) Y~) oflCG by GNP with distance from GNP is shown
in Figure 10. Previously the values for other fluorophores were presented in logarithmic
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scale (Fig. 6), but to provide a better view of the values for leG in the distance and to
compared it to the excitation rate, here, the values are presented in a linear scale. The
absorption rate on the GNP surface is extremely high (~ 1 06) , but the rate decreases very
fast with distance. Fig. lOb shows the magnified section of the absorption rate in the
distance range of 2-10 nm. At 2 nm, it already decreases to 470. The absorption still
decreases fast after 2 nm. At 5 nm, the absorption decrease to 33 , and at 10 nm, 4.4, a
similar magnitude as the radiative decay rate and smaller than the intrinsic quantum yield
effect (l- qO)/qO(Table 3).
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Figure 10. (a) Absorption rate ( YlIbS/Y;) of leG by a 30 nm GNP, with
respect to the distance from the GNP surface (b) magnified view of the
section in the rectangle in (a)

Figure 11 shows the quantum yield change of leG near the GNP at various sizes,
which is the combined effect of the in radiative decay rate, absorption rate and intrinsic
quantum yield. Bigger GNPs provide greater quantum yield. When the distance is less
thanl nm, the quantum yield is highly reduced due to the strong absorption shown in Fig.
lOa. As the distance increase, the absorption decreases much faster than the radiative
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decay rate, and the quantum yield increases until it reaches the maximum, and decreases
thereafter.
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Figure 11. Theoretically computed quantum yield change of leG (Ex/Em

780/830 nm) with the distance from the GNP at various sizes

The fluorescence output is the product of the excitation rate and the quantum
yield (Eq. 9; Figs 9 and 10). Figure 12 shows the fluorescence change of leG by a GNP
of the size

5 ~50

nm. With 5 nm GNP, the leG fluorescence is quenched within 4 nm. At

the distance longer than 4 nm, the level is similar to that without the GNP. Therefore, 5
nm GNP may be effectively used as a quencher for leG. For the 10 nm GNP, the
fluorescence is quenched only within 1.3 nm from the GNP, and gets enhanced thereafter.
It reaches the highest enhancement (2.4 times) at 3.4 nm. As the GNP size increase, the

distance for quenching

becomes even shorter, and the maximal fluorescence

enhancement becomes higher. In general, the distance for the maximal enhancement is
shorter than those for other fluorophores. For bigger GNPs, the distance for maximal

65

enhancement is longer, as for other fluorophores. For the 15, 30 and 50 nm GNPs, the
maximal enhancements are 5, 14, and 26 times, at the distance of 3.4, 3.9 and 4.4 nm,
respectively. The enhancement values are much greater than those for the other
fluorophores studied, mainly due to its very low intrinsic quantum yield.
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Figure 12. Theoretically computed fluorescence emission ofICG (ExlEm
780/830 nm) with the distance from the GNP of various sizes

As can be seen from Figs. 8-12, the fluorescence alteration of ICG features a
unique pattern. Both quenching and the maximal enhancement occur within a short

(~5

nm) distance range. This unique property became the basis for our design of the contrast
agent that conditionally changes fluorescence level from quenching to enhancement at
presence of a particular enzyme, which is presented in the experimental section of this
dissertation.
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B. EXPERIMENTAL STUDY

ICG fluorescence is predicted to be changed by GNP from complete quenching to
extensive enhancement, within 5 nm from the GNP surface as shown in the theory
section (Fig. 12). Utilizing this unique property, a novel optical contrast agent for
molecular imaging was designed (Fig. 13). As a model system, the contrast agent was
developed for breast cancer detection.
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Figure 13. (a) Design of highly cancer specific fluorescing cancer locator.
The agent normally does not emit fluorescence because the short spacer
place Cypate very close to the GNP. (b) When the cancer locater binds to
the cancer cell, it is exposed to the cancer secreting enzyme. The short
spacer is cleaved by the enzyme from cancer cell and the fluorescence is
emitted at an enhanced level.

1. Components of the Contrast Agent
The components of the contrast agent are: a GNP, the materials for GNP surface
treatment (sPEG) , spacers (SSP and LSP), Cypate and targeting molecules.
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(a) GNP

In our experimental studies, the GNP core at the sizes of 5, 10 and 15 nm were
used. It should be noted that the sizes 5, 10 and 15 were the ones claimed by the
manufacturer. The actual sizes according to our measurements by the light scattering
analysis and TEM were 3.7,8 and 16.4 nm, respectively.

(b) GNP surface modification

The SAM of HS-(CH2)w(CH2CH20)3 (sPEG) was used to stabilize GNPs. The
HS- group is for reacting to GNP surface. The hydrocarbon chain section (-1.5 run by the
molecular simulation) of sPEG is straight and hydrophobic for tight packing on the GNP
surface, and the PEG section (0.9 run by the simulation) is flexible and hydrophilic. The
length estimation was done by a computer code assuming that the molecule was in an
extended configuation in vacuum, and, therefore, the actual length may be slightly
different in the physiological conditions.

(c) Spacers
(c-i) Short spacer (SSP)

A short spacer was used to place Cypate at a distance from the GNP for its
fluorescence to be quenched. The spacer must contain a motif that can be cleaved by a
cancer-secreting enzyme. In our model system, the enzyme was urokinase-type
plasminogen activator (uP A). uP A is expressed in a number of malignant breast cancers.
The Gly-Gly-Arg amino sequence is a substrate of uPA, and, therefore, our short spacer
was HS-(CH2)2-Gly-Gly-Arg-Gly-Gly-Gly-NH 2 (or -ONH2). The HS- ending is for
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binding it to the GNP surface and the -NH2 or -ONH2 ending is to link it to Cypate or mCypate.

(c-ii) Long spacer (LSP)

The long spacer is to keep the distance between Cypate and the GNP at the length
producing the maximum fluorescence enhancement. The spacers were designed to have a
similar structure as the sPEG to allow the LSP forming a well-mixed monolayer with
sPEG on the GNP surface. They were HS-(CH2)m-PEGn-ONH2. By varying the numbers
m (12 or 16) and n (4, 6 or 8), the length of the spacer was varied. The -ONH2 ending is

for m-Cypate conjugation.

(d) Fluorophore

Our fluorophore is Cypate, an ICG derivative. ICG does not have any functional
group to conjugate biomolecules (Figure 14a). Achilefu, et al. [2000; 2002] slightly
modified the structure of ICG and created Cypate with two carboxylic groups (Figure
14b), which can then react to amine groups of biomolecules by using a coupling agent to
activate the carboxylic groups. However, there are many biomolecules with carboxylic or
amine groups. Therefore, we decided to use -CHO/-ONH2 reaction. The Nantz-group, our
research partner, added adelhyde (-CHO) groups to the carboxylic ends of Cypate to form
a modified-Cypate (m-Cypate; Figure 14c). The adelhyde group allows the oxime
coupling with the aminooxy ending (-ONH2), forming stable oxime bound. This reaction
does not require additional coupling agent and is not interfered by other peptides and
proteins.
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If only one of the two -CHO endings of m-Cypate needs to be reacted, blocking
agent (BLK), (CH3hN+-(CH2)2-0NH2, was used to block one ending. The BLK also
helps to increase the hydrophilicity of Cypate, preventing from m-Cypate being adsorbed
to the hydrophobic hydrocarbon chain of the sPEG or LSP.

Figure 14. Molecular structures of (a) ICG and (b) Cypate (Supplied by
the Achilefu group) (c) m-Cypate (Modified by the Nantz group)

(e) Targeting molecule

Tamoxifen and Herceptin are selected to be the targeting molecules. Tamoxifen is
a drug currently used to treat estrogen receptor positive (ER+) breast cancer. It works as
an antagonist that binds to the ER, which is over-expressed in 70% of breast cancer.
Herceptin is an antibody that binds to Human epidermal growth factor receptor 2
(HER2), which is over-expressed in 20-30% of early-stage breast cancer.

This contrast agent is to emit little fluorescence (the fluorescence is to be
quenched). It is to be preferentially delivered to the cancer site via the targeting molecule
(Fig. 1Ob). The the agent is placed in an environment with uP A. When the short spacer is
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cleaved by uP A, the distance between the Cypate and the GNP is now at the long spacer
length. The fluorescence changes from a quenched level to an enhanced level, detecting
the cancer with high specificity and contrast.
The development steps of this contrast agent were as follows:
1. Characterization of individual components of the system
2. Optimization of spacers
(a) Optimization of the short spacer (conditional fluorescence quenching)
(b) Optimization of the long spacer (maximal fluorescence enhancement)
(c) Construction and testing the dual-spacer
3. Conjugation of targeting molecule
4. Cell study
In this dissertation the results from the steps 1, 2, and a part of 4 are presented.

2. Characterization of the Components
(a) The effect of the solvent on Cypate fluorescence
Cypate is hydrophobic due to its aromatic part and long polymethine chain. It has
a low solubility in water and forms aggregates in water [Licha, et al., 2000]. The intrinsic
quantum yield (QY) of Cypate in water (0.0028) is lower than that in blood plasma
(0.012). One way of avoiding the Cypate aggregation in water is by increasing the ionic
strength in water. Figure 15 shows the fluorescence of Cypate in water, and 10 mM PBS.
The Cypate fluorescence is extremely low in water. In PBS, the Cypate fluorescence is
approximately 150 times higher than that in water. The fluorescence in 1 mM PBS is
similar to that in 10 mM PBS (only 7% less). Colloidal GNPs stabilized with citric/tannic
acids, without special surface treatment, easily precipitate in the solutions with high ionic
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strength (e.g., 10 mM PBS buffer). Therefore,

In

the preliminary studies involving

colloidal GNPs, 1 mM PBS buffer was used.
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Figure 15. Fluorescence of Cypate in water, 1 and 10 mM PBS buffer
(Cypate concentration: 30 J..lM)

(b) Cypate concentration and self-quenching

Fluorophores quench their own fluorescence when their concentration exceeds a
certain level (inter-molecular quenching), either by the collision among excited and
ground-stated fluorophores (dynamic quenching) or by forming the ground-stated
fluorophore complexes (static quenching) [Ingle and Crouch, 1988; Johansson, et
2002].

at.,

To avoid the inter-molecular quenching, we have observed the Cypate

fluorescence level with respect to the concentration at a range of 5~ 150 !lM (Fig. 16).
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Figure 16. Fluorescence ofCypate at various Cypate concentrations (in 10
mM PBS)

The fluorescence increased with the increase in Cypate concentration up to 30
flM. At concentrations higher than 30 flM, the fluorescence decreased. Therefore, the
Cypate concentration less than 30 flM was used for further studies.

(c) Fluorescence of free Cypate affected by free GNP colloids

One simple way of changing the average distance between the GNP and the
Cypate is by varying the concentration of GNPs. The fluorescence of free Cypate affected
by colloidal GNPs of various concentrations was studied for 5 and 10 nm GNPs at a
weight (wt) concentration range of 0-60 /lg/ml (molar concentration: for 5 nm GNP,
0-75 nM, and for 10 nm GNP, 0-8.5 nM) at a Cypate concentration 30 flM, which is the
maximum concentration without self-quenching (Fig. 17). In this experiment, GNP
concentration is, therefore, the limiting factor.
When the GNP concentration is very low
fluorescence.

« 6 /lg/ml), the GNPs enhanced the

This phenomenon may be explained by figure 15. For free GNPs and
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fluorophores, when the fluorophore concentration is fixed, the distance between the GNP
and fluorophore is determined by the GNP concentration.
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Figure 17. Fluorescence of free Cypate with various concentrations of free
GNP (Cypate concentration for both GNP sizes 30 nM).

At concentrations greater than 6 Ilg/ml (for 5 nm GNP, 8.3 nM, for 10 nm GNP,
1.0 nM), the fluorescence was quenched, and the quenching level increased with the
increase in GNP concentration.

At the same wt concentration, 5 nm GNPs showed

greater quenching than those at 10 nm, probably because the number of 5 nm GNPs is 8
times greater than that of 10 nm GNP, and the total surface area is about 2 times larger.
Also, due to its smaller size, 5 nm GNPs would have much greater mobility than 10 nm
GNPs would, resulting in greater probability for Cypate to be near the GNP. In addition,
as shown in the theory section, smaller GNPs tend to cause quenching.
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When the GNP concentration is very low [Fig. 18(b), with one GNP] , the average
distance between Cypate and GNP is longer, and the fluorescnece is either slightly
enhanced or unaffected. At a higher GNP concentration [Fig. 18(a), with three GNPs] ,
the distance between GNP and Cypate is shorter and, thus, more Cypate molecules are
near the GNP surface, resulting in more fluorescence quenching.
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Figure 18. Schematic diagram for fluorescence of free Cypate affected by
(a) high and (b) low GNP concentration in solution

As a preliminary study, this result verified that the GNPs affect Cypate
fluorescence from quenching to enhancement, depending on the GNP concentration
(distance between GNP and Cypate).

3. Optimization of Spacers
(a) Short spacer
Figure. 19 is a schematic diagram demonstrating the mechanism of the short
spacer in the contrast agent of our interest. sPEGs are packed on the GNP surface for
stabilizing the GNPs. Cypate is conjugated to GNP via the short spacer. The methods for
conjugating Cypate to GNP via short spacer were: (1) Cypate (Cy) conjugated SSP (CySSP) was mixed with sPEG at a predetermined ratio and the mixture was reacted with
GNPs to form a monolayer of two different molecules on the GNP surface, or (2) The
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SSP with the - ONH2 ending (nSSP) was mixed with sPEG at a predetermined ratio and
the mixture was reacted with GNPs to produce GNP-nSSP. Then the m-Cypate reacted
with BLK was reacted to the GNP-nSSP .
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Figure 19. A schematic diagram of the uPA triggered fluorescence
contrast agent, Cypate conjugated GNP via a short spacer: (a) normally
emits little fluorescence (b) in the presence of uP A enzyme, the spacer is
cleaved and the fluorescencing ability of the agent is restored.

For our system, SInce the short spacer and the fluorophore were already
determined, the only parameter that could be varied was the GNP size. Theoretical study
results suggested that smaller GNPs provided more effective quenching with the same
distance between the GNP and the fluorophores. We, therefore, decided to first test
relatively smaller GNPs, i.e. 3.7, 8.9 and 16.4 nm GNPs.

(a-i) Characterization of GNP-SSP-Cy

The GNP-SSP-Cy produced was characterized by UV -Visible spectroscopy to
confirm the presence of both GNP and Cypate and to study their optical properties.
Figure 20(a) shows the absorption spectra of GNP, SSP-Cy and GNP-SSP-Cy when 8.0
nm GNPs were used. GNPs and SSP-Cy show their signature absorption peaks at 520 and
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780 nm, respectively. GNP-SSP-Cy shows the peaks of both GNP and SSP-Cy. The
peaks were slightly red-shifted, probably due to the changes in the refractive index of the
GNPs after the polymer conjugation.
GNP-SSP-Cys were spread on TEM grid as a monolayer and dried under vacuum.
TEM was performed to visualize the GNP core and potentially the coating [Fig. 20(b)].
The image shows a uniform GNP core size of 8.0 nm. The sPEG coating is not visible
because usually polymers do not respond to the electron beams well. Since TEM requires
the sample to be dried and is performed in a high-vacuum, the image may not show the
dispersion property of GNP-SSP-Cy in solution. Nonetheless, the particles are separated
from each other at a constant distance, which is speculated to be the thickness of two, dry
sPEG layers. Dynamic light scattering particle size analyzer was not used for this GNP
product due to the interference caused by the Cypate fluorescence.
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Figure 20. (a) Absorption spectra of GNP, SSP-Cy and GNP-SSP-Cy, and
(b) TEM image ofGNP-SSP-Cy [GNP, 8.0 nm]
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(a-ii) Effect of the GNP size on fluorescence quenching
The fluorescence levels for the GNP-SSP-Cy products with GNP core size of 3.7,
8.0, 16.4 run, were observed and compared with that of SSP-Cy alone (Fig. 21). The
Cypate concentration in all GNP-SSP-Cy samples was adjusted to 10 IlM, using the
absoption at 780 run. At this Cypate concentration, the GNP concentration determined by
520 run absorption were 31 , 7, 4.2 nM for 3.7, 8.0 and 16.4 run GNP, respectively.
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Figure 21. Relative fluorescence of the GNP-SSP-Cy with
the core GNP size of 3.7, 8.0 and 16.4 run at 10 IlM
Cypate concentration in PBS buffer

For 3.7 and 8.0 run GNPs, the fluorescence was quenched by 95% and 94%,
respectively. For 16.4 run GNP, however, the fluorescence was enhanced by 120%.
Therefore, 3.7 and 8.0 run GNPs were used in our further studies.
Figure 22 shows the theoretical estimation of the fluorescence of Cypate placed
near a GNP of 3.7, 8.0 and 16.4 run. It shows that to obtain the fluorescence alteration
level shown in Fig. 21 , the spacer lengths should be 0.4, 0.3 and 1.5 run, for 3.7, 8.9 and
16.4 run GNPs, respectively. They are much shorter than the SSP length that we
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estimated by the simulation, although the trend that bigger GNP results

III

higher

fluorescence qualitatively agrees with the experimental results.
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Figure 22. Theoretical estimation of fluorescence emission
with the distance from the GNP surface for the GNPs sizes
at 3.7, 8.0, and 16.4 nm for ICG (Ex/Em 780/830 nm)

The discrepancy between the experimental result and theoretical prediction may
be because:
(1) The length estimation for SSP was done by a molecular simulation assumes SSP

to be extended configuration in vacuum, while in the actual system they were in
a water based buffer and may not be linear.
(2) The theoretical result shown in Fig. 22 was for bare GNPs. In our experimental
system, the GNPs were coated with sPEG, and Cypate is outside the sPEG layer,
where the plasmon field may be slightly stronger than the one without sPEG
coating (See Fig. 7).
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(3) The theoretical model is based on a system with a single fluorophore and a single
GNP with no inter-particle or inter-fluorophore interference. In the experimental
study, multiple fluorophores were conjugated to a single GNP, and multiple
GNP-SSP-Cys were dispersed in the solution. There may be interaction among
the particles and fluorophore molecules, e.g., self-quenching may occur among
the Cys on the GNP and the fluorescence of GNP-SSP-Cy may be affected by the
GNP of another GNP-SSP-Cy nearby.
(4) The theoretical analysis here was done only in one direction (8 =0), i.e., the
effect of other directions were not considered, while, in the experimental system,
Cypate is conjugated all around the GNPs. The field strength varies with S, thus
the fluorescence alteration value is also different for different S.
The theoretical and experimental results, however, qualitatively agree in the sense
that, at the same distance from the GNP surface, smaller particles provide less
fluorescence.

(a-iii) Conditional fluorescence restoration

Our model system is to fluoresce only in the presence of uPA. The GNP-SSP-Cy
products showing the fluorescence quenching (i.e., with 3.7 and 8.0 nm GNP cores) were
tested with a sufficient amount of uP A (1030 units/mI), and their fluorescence changes
were observed. Figure 23 shows the fluorescence levels of the GNP-SSP-Cy before and 5
minutes after uPA was applied. The fluorescence of 3.7 and 8.0 nm GNP-SSP-Cy was
restored up to 21 and 43%, respectively.
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Ideally, when uPA reacts with the GNP-SSP-Cy, the fluorescence is to be
completely (100%) restored. The possible reasons for this partial fluorecence restoration
were: (i) the Cypate molecules freed from the GNPs would be still placed very close to
GNPs because of the high GNP concentration and the fluorescence niight be still
quenched; (ii) SSP and sPEG molecules might be packed tightly on the GNP surface and
uPA would not have easy access to the uPA-substrate site in the SSP. This may be
resolved by replacing sPEG with shorter PEG molecules; and (iii) the released Cypate
molecules might have been adsorbed at the hydrophobic site of sPEG.
We have first tested the hypothesis (i). The relative fluorescence of 10 nm GNPnSSP-mCy before and after adding uPA was observed at various GNP concentrations,
while the mCy/GNP ratio is fixed (performed by Dr. Robert Lupitskyy; Fig. 24). The

81

GNP concentrations tested (2.5 , 5, and 10 nM) were in the range of the concentration
used in our previous studies [Fig. 17 (7 nM)].
The GNP-nSSP-mCy as it is, showed very little fluorescence «5% of the
control). When uP A was applied to the sample, the fluorescence restoration for the GNP
concentration of2.5 , 5, and 10 nM were 71 , 42 and 12%, respectively, indicating that the
restoration rate is highly affected by the GNP concentration in the solution. We expect
that at a lower GNP concentration the fluorescence will be fully restored. We were,
however, not able to further lower GNP concentration, because at the GNP concentration
at 2.5 nM, the mCy concentration reaches the lower limit

(~40

nM) for a reliable

fluorescence measurement.
This result suggested that the higher GNP concentration [i.e. (i) described above]
may be the major cause for the low fluorescence restoration.
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82

(b) Long Spacer

The main role of the long spacer (LSP) is to maximize the Cypate fluorescence for
a GNP size selected. The theoretical results (Fig. 12) shows that the enhancement level is
determined by the distance and the GNP size. For the spacers, the LSPs previously
described (B-l. components of the contrast agent, b-ii) were tested for the Cypate
fluorescence enhancement. For the GNP size, bigger GNPs provide a greater maximum
enhancement and require a shorter distance for fluorescence quenching. For our system,
however, the length of the short spacer was already fixed, and therefore, to maintain a
satisfactory level of quenching the upper limit of the GNP size to be used was already
determined. The GNP size to be tested for our system was therefore decided to be less
than 20 nm (3.7,8.0 and 16.4 nm).
As previously described, sPEG is used for GNP surface modification and also for
adjusting the spacing between the two adjunct fluorophores on the GNP surface. After
testing several LSP-to-sPEG ratios, 1:9 was found to be working well without causing
aggregation. The purified GNP-LSP was then reacted with m-Cypate (with BLK) to
produce GNP-LSP-mCy.

(b-i) Characterization of GNP-LSP

According to our theoretical study results for the GNPs at a size range of 5-50 nm
that enhance the ICG fluorescence, the distance between a GNP and ICG is in a range of
2-5 nm. Table 4 listed the spacers used in this study and their lengths estimated by a
molecular simulation. Again, the mathematical model used to compute the length of the
spacers assumes that the molecule is straight and in vacuum.
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Table 4. Spacers used and their estimated lengths by molecular simulation
Spacers

Abbreviations

HS-(CH2)/rPEGTOH
HS-(CH2)12-PEG4-0NH2
HS-(CH2)16-PEG4-0NH2
HS-(CH 2)IZ-PEG 6-ONH 2
HS-(CH2)WPEG6-0NH2
HS-(CH2)12-PEG8-0NH2

sPEG
C12PEG4
C16PEG4
C12PEG6
C16PEG6
C12PEG8

Extended Length (nm)
230*
3.20
3.69
3.90
4.41

4.60

* sPEG is the coating material
In an attempt to verifY the spacer conjugation and also to know the actual length
of the spacer, the GNPs conjugated with the SPs and sPEG were characterized by the
dynamic light scattering (DLS) size analysis and TEM.
Table 5 shows the particle size measured by DLS, before and after the
conjugation.
Table 5. Size ofnanoparticles, before and after conjugating sPEG and
sPEGILSP, measured by light scattering particle size analyzer
Sample

5nmGNP

Uncoated GNP
GNP-sPEG
GNP-sPEG/C 12PEG4
GNP-sPEG/C12PEG6
GNP-sPEG/C 12PEG8

3.7 ± 0.9
8.0 ± 1.6
8.3 ± 1.1
11.2 ± 2.3
10.1 ± 1.6

10nmGNP
8.0 ± 1.5

10.2 ±
11.2 ±
10.5 ±
11.5 ±

0.9
1.2
1.7
1.9

15 nm GNP

16.4 ± 0.90
17.5 ± 1.3
17.9±1.2
18.1 ± 3.1
17.0±3.8

The diameter of the particles increased by 1.5-7.5 nm after coating. In general, the
increase in diameter measured by DLS appeared to be much less than those theoretically
estimated (6.4-9.2 nm, double of the length of the SPs), indicating that the actual length
of the sPEG of spacers may be shorter than the estimation. In addition, the difference in
the size between the GNP-sPEG and the GNP-sPEG/SPs was minimal, possibly because
the majority molecules on GNP surface are sPEG. For bigger GNPs, the increase was less
than the ones for smaller particles. DLS measures the hydrodynamic diameter of particles
based on the diffusion of particles in the fluid. With the same polymer coating thickness,
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the movement of a particle with a bigger heavy (gold) core may be less affected by the
light coating, results in less change in the particle size.
The particles were also imaged by TEM. Because TEM does not usually respond
to organic polymer well, therefore, we put an extra effort to spread diluted GNP products
on the TEM grid so that the particle solution formed a thin particle monolayer. The
spacing between two adjacent particles was expected to be the thickness of two layers of
spacers on GNP. Figure 25 shows the 8.0 nm GNPs conjugated with (a) sPEG and (b)
sPEG and C12PEG6 spacer. The distance between two adjacent particles were measured
at least 50 different arbitrarily selected locations and the mean distance was 1.2±0.1 nm
for all samples. Again, no notable difference in layer thickness was observed among the
GNPs coated with various spacers, probably because the polymer layer thickness in the
TEM was represented mainly for sPEG. It should also be noted that the samples prepared
for the TEM were dried under vacuum, and therefore, the actual thickness of the coating
layer in aqueous solution may not be the same as the one shown in TEM images. A
technique that can be used for this type of analysis is urgently needed for bio-nano
research.

(a)

(b)

Figure 25. TEM image of8.0 nm GNPs coated with (a) sPEG only and (b)
sPEG and C 12PEG6
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(b-iii) Spectroscopic analysis of GNP-LSP-mCy

GNP-LSP-mCy was characterized by UV -Vis spectrometry to confirm the Cypate
conjugation. Figure 26 shows the absorption spectra of GNP, GNP-sPEG, GNP-

sPEGILSP, GNP-LSP-mCy and mCy.
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Figure 26. Absorption spectra of 8.0 run GNP, GNP coated with sPEG
alone, with sPEG and C12PEG6, GNP-LSP-mCy, and mCy

The absorption spectrum of GNP-sPEG is very similar to GNP except that the
absorption peak was slightly red-shifted, caused by the changes in refractive index by the
polymer coating. When the GNP is coated by both sPEG and LSP (C12PEG6), the peak
showed a slightly greater red-shift. After reacting mCy onto the GNP via the LSP, the
spectra showed both GNP and mCy absorption peaks. The concentrations of GNP and
mCy were estimated by the absorption at their respective signature wavelengths.
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(b-iv) Application of blocking agent for m-Cypate
For binding Cypate to GNPs via the LSPs, initially mCy was reacted to GNP-LSP,
as it was, without using BLK. After the product was purchased and tested for the
fluorescence emission, strong fluorescence quenching was observed for all the LSPs. We
speculated that the quenching might be caused by one or both of the following potential
reasons (Fig. 27a): (i) mCy has two -CHO groups that can react to the -ONH2 group of
the spacers. Therefore, it may react to two LSPs on the same GNP or on different GNPs,
and the later may place GNP very close to mCy, or (ii) Cypate is hydrophobic and it may
be adsorbed to the hydrophobic -(CH2)m- part of sPEG and LSPs (Fig. 27a), before or
after it binds to LSPs. Thus the distance between the mCy and GNP surface becomes
short and it leads to fluorescence quenching.
To resolve these issues, (CH3)3N+-(CH2h-ONH2 was used as the blocking agent.
It was mixed with mCy at a 1: 1 molar ratio, assuming that it blocks one of the two CHO

groups of mCy so that each mCy reacts to only one LSP (Fig. 27b). Since BLK is
hydrophilic, it is expected to increase the hydrophicility of mCy and thus helps avoid
adsorption of mCy to the hydrophobic inner layer on GNP surface. With the use of BLK,
the quenching problem disappeared and fluorescence enhancement with respect to spacer
length and GNP size was observed instead of quenching.
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Figure 27. Schematic diagram of the function of blocking agent. (a)
Without BLK (i) m-Cypate reacts to more than one LSPs and is placed
very close to GNPs or (ii) m-Cypate is adsorbed to the hydrophobic
section of sPEG and LSP. (b) One of the two -CHO group on m-Cypate is
blocked therefore each LSP reacts to one m-Cypate, and m-Cypate is not
adsorbed to the hydrocarbon chain close to the GNP surface.

(b-v) Effect of LSP length on fluorescence enhancement

Figure 28 shows the relative fluorescence of the GNP-LSP-mCy at various LSP
lengths [HS-(CH2)m-PEGn-ONH2, m=12 or 16, n=4, 6, or 8; 3.2-4.6 nm], when 8 nm
GNP was used.
The shortest spacer, C12PEG4 (simulated length estimation, 3.2 nm), resulted in a
fluorescence quenching by 14%. For C16PEG4 (3.7 nm) , the fluorescence was enhanced
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by 36%. The fluorescence of GNPs with C12PEG6 (3.7 nm) and C16PEG6 (3.9 nm)
showed the enhancement of two times. For the spacers longer (C12PEG8, 4.6 nm) than
these two the fluorescence enhancement started to decrease.
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Figure 28. Relative fluorescence ofmCy conjugated to 8.0 nm GNP via
spacers with various lengths

When the results of theory and experiment were compared (Fig. 29), the level of
the maximum enhancement was similar (- 2 times). However, the distance showing the
maximum in the theoretical result was slightly shorter than the corresponding
experimental spacer lengths. If the theoretical values were shifted by 1 nm (dotted line),
they fit to the experimental values well except the value for the spacer C12PEG8. The
reason for this discrepancy may be that the spacer length in the aqueous environment may
be slightly different from those estimated by the simulation with the assumption that the
molecule is straight and in vacuum.
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Figure 29. Relative fluorescence ofmCy-BLK conjugated to 8.0 nm GNP
via the spacers with various lengths, compared to the theoretically
estimated fluorescence.

(b-v) Effect of GNP size on fluorescence enhancement
Theoretical study results show that, in general, bigger GNPs provide the greater
fluorescence enhancement. We experimentally tested the changes in the Cypate
fluorescence caused by three different GNP sizes (3.7, 8.0 and 16.4 nm). For this study,
the spacers, C12PEG4 (3.2 nm), C12PEG6 (3.9 nm) and C12PEG8 (4.6 nm) were used.
Figure 30 shows both theoretical and experimental results of fluorescence
alteration by 3.7, 8, and 16.4 nm GNP.
When 3.7 nm GNPs were used, the Cypate fluorescence was quenched for all
spacers. The shortest spacer, C12PEG4 (3.2 nm), resulted in the most quenching (60%)
as expected, and C12PEG6 (3.9 nm) and C12PEG8 (4.6 nm) showed the quenching of30
and 40%, respectively. These results indicates that the 3.4 nm GNP may be too small to
enhance the Cypate fluorescence, but it can be used as an effective quencher, and a
shorter spacer may be desired for greater quenching. The experimental results

90

qualitatively agreed with the theoretical predication, although the two results fit better
when the theoretical result is shifted by 1 run.
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For 8.0 run GNP, the result has already been discussed.
With the 16.4 run GNP, C12PEG4 caused 50% quenching, while C12PEG6 and
C12PEG8 provided the enhancement of 3.6 and 2.7 times, respectively, greater than that
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by the 8.0 run GNP (2 times). When it is compared to the theoretical results, the
magnitudes of fluorescence changes by the spacers C 12PEG4 and C 12PEG6 are similar
to those by the theoretical results that are shifted by 2 run in the x-axis. However, the one
with C 12PEG8 was significantly lower than the theoretical value.
Both theoretical and experimental results confirmed that for fluorescence
enhancement, GNP size needs to be sufficiently large, and bigger GNPs provide the
greater maximum enhancement. The results also show that the spacer length needs to be
carefully selected to obtain the maximal enhancement. When the experimental results
were compared to the theoretical values, the estimated length of the spacer used in the
experiment were 1-2 run longer than those of the theory. This phenomenon was observed
in the short spacer study and previous studies from the Kang group [Kang, et al., 2011;
Wang, et al., 2011], and the possible causes for the discrepancy have been discussed in
the short spacer study. Although the exact reasons for this discrepancy were not fully
understood yet, the difference is not significant. Therefore, the theoretical prediction is
still very valuable in selecting the proper parameters for developing appropriate contrast
agents using GNP, which reduces the number of experiments significantly.
In the process of designing and finalizing our dual spacer an important constraint
is that the conditions need to satisfy both short and long spacer performance. Although
16.4 run GNP provides the greatest fluorescence enhancement, it does not quench the
fluorescence with the short spacer. Therefore, for the dual spacer system, 8.0 nm GNP,
which provides quenching and enhancement with the SSP and LSP respectively, was
decided to be used.
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(c) Dual-spacer
(c-i) Design of the dual-spacer
In the original design of the dual spacer (Fig 31) , one of the two -COOH groups
of Cypate is conjugated to a short spacer and the other, to a long spacer (DSP-Cy) .
Ideally , Cypate is to be connected to GNP by both spacers as shown in Fig. 31. However ,
the design may easily produce several undesired products as shown in Fig. 32, especially
because there is a difference in length of the two spacers. Sometimes only one spacer
may be attached to a GNP and the other spacer is free. Some times two spacers are
attached to two different GNPs and multiple GNPs are connected by the spacers (crosslinking). Slight cross-linking may be tolerable, because fluorescence will be quenched as
long as Cypate is conjugated to GNP via the short spacer, and at least it does not emit
non-specific fluorescence. Severe cross-linking may result in the GNP aggregation.
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sPEG

,./

(0 "'- J
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Long / ,
spacer

i "

Short spacer

Cypate

Figure 31. Original design for the synthesis of GNP-DSP-mCy (ideal case)
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(a)

(b)

Figure 32. Potential undesired product (a) incomplete conjugation (b)
cross linking from the original design for the synthesis of GNP-DSP-mCy

In addition, the synthesis of DSP-Cy has been difficult. The Nantz group has
attempted to synthesize the DSP-Cy via the approaches of (1) solid-phase amide
coupling, (2) solid-phase oximation coupling, and (3) solution-phase oximation coupling
(from their report to DOD). None of them were successful due to the damage in Cypate
molecule during the purification process.
We, therefore, took a new approach to resolve these issues: A ring-shaped dual
spacer (rDSP) was designed (Fig. 33). The design was commissioned to a company to
produce it (NeoGroup Inc., Cambridge, MA) . In the rDSP, the two ends of long spacer
are attached to the two ends of the short spacer, making a circular shape. The rDSP has
one single -SH group for reacting to GNP surface, and a single -ONH2 group for reacting
with m-Cypate. This rDSP can be used to connect m-Cypate to GNP in the same manner
that the nSSP or LSP does.
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Fi gure 33. The chemical structure of the ring-shaped dual spacer (rDSP)

To facilitate the synthesis of the rDSP , the structures of the short and long spacers
were

slightly

modified.

Our

short

spacer was

HS-(CH2)2-NHC(O)-GGRGGG-

C(O)(CH2)-ONH2. Here, the following modifications were performed: at the -SH end,
HS-(CH2)2-NH- was replaced by HS-CH2-CH(NH2)-C(O)- which provides a side group
for connecting the new long spacer section later. At the -ONH2 end for Cypate reaction, CH2-ONH2 was replaced by -NH-CH(COOH)-CH2-NH-C(O)-CH2-0-NH2' which has a
side group -COOH for connecting the long spacer later. However, it introduces extra
length [-CH(COOH)-CH2-NH-C(O)-]. To keep the length of the short spacer to be short
for quenching while maintaining the peptide substrate function, we removed one Glycine
in the peptide sequence, having -GRGGG- instead of -GGRGGG-.

CH2-CH(COOH)-NH2 provides the ,SH group, which gives and extra length of -CH2CH2(COOH)-NH-. For the -ONH2 end, using H2N-CH(COOH)-CH2-NH-C(O)-CH2-0-
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NH2 results in extra length of C(O)-CH2-CH2-NH-C(O)-CH2. Hydrocarbon chain and
PEG are connected through amide-bond, which also introduce extra length [-NH-C(O)-].
To compromise these length increases and maintain the total length similar to our long
spacer, the -CH2- number was reduced from 12 to 6, and EG number was reduced from 6
to 5.

(c-ii) Characterization and performance of the rDSP

The absorption spectra of GNP, m-Cypate and GNP-rDSP-mCy are shown in
Figure 34. The GNP-rDSP-mCy showed both GNP and mCy absorption peaks,
confirming the conjugation.
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Figure 34. Absorption spectra of 8.0 nm GNP, GNP coated sPEG, GNPrDSP-mCy, and mCy

Figure 35 shows the relative fluorescence of GNP-rDSP-mCy (GNP size, 8.0 nm)
and after uP A was applied.
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Figure 35 . Fluorescence of GNP-rDSP-Cy (8.0 run GNP) at 100 nM
Cypate, 0.9 nM GNP, before and after adding uPA at 1030 units/ml
(Ex/Em 780/830 run)

The fluorescence of GNP-rDSP-mCy was quenched by 93%, very close to the
one with GNP-SSP-Cy (94%). When uPA was added, the fluorescence increased to 1.8
times of the m-Cypate, which is slightly lower than the enhancement for the 8.0 run GNP
with the LSP (2 times).

In summary, with 8.0 run GNP, the rDSP provided the fluorescence quenching of
93%, and the fluorescence enhancement of 1.8 times, upon uP A addition. This result
confirms the functionality of the design of the novel contrast agent utilizing both
fluorescence quenching and enhancement by GNPs.

4. Cell Study
(a) Short spacer performance
The GNP-SSP-Cys showing satisfactory performance of the fluorescence
quenching, and the restoration with uP A addtion (in PBS buffer) were tested for the
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selected breast cancer cell lines. Two cell lines tested were: MCF-7 cells known to
secrete little uPA (uP A-) as a control, and MDA-MB-231 cells expressing high level of
uPA (uPA+). uPA+ cells produce and release uPA from the cells to the surrounding
media. Therefore, the uP A concentration in the media increases with time. Here the cells
were cultured in serum-free media and incubated for a predetermined time to let the uPA
accumulate in the media.

(a-i) uP A secretion of the cell lines
To see the feasibility of our contrast agent in cell culture systems, before testing
the GNP-SSP-Cy, the uP A concentration and its activity of the cell lines in the media
needed to be confirmed. The cell study was done in the Bates group at University of
Louisville, with the help of the group members (Dr. Tariq Malik and Ms. Levona Coxon).
The uPA concentrations in the media were measured 8 and 32 hrs (arbitrarily chosen)
after the cells were plated. The uPA quantification was done by enzyme-linked
immunosorbent assay (ELISA). At 8 hrs, the uP A concentrations in both cell lines were
at the lower limit of the ELISA, with a high noise level generated among the 4 duplicates
of the sample (Fig. 36). At 32 hrs, MCF-7 cell line (uPA-) showed a low level (0.76±0.65
ng/ml) of uP A. Nevertheless there was uPA in the medium. The MDA-MB-231 (uPA+)
cell line showed the uP A concentration of 3 .15± 1.20 ng/m!. This concentration was
approximately 1000 times lower than the concentration used in our experiments in PBS
buffer (2~ 10 flg/ml).
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Figure 36. uPA concentrations in the media containing MCF-7 (uPA-) or
MDA-MB-231 (uPA+) cells, after 8 and 32 hrs of cell culturing

(a-ii) Fluorescence change of GNP-SSP-Cy in cell lines

The GNP-SSP-Cy with 8.0 nm GNP core was tested in MCF-7 (uPA-) and MDAMB-231 (uPA+) cell lines. This experiment was performed by Dr. Sharon Bloch in the
Achilefu group at Washington University. The cells were plated and cultured for 32 hours
to have a sufficient amount of uP A. GNP-sSP-Cy samples at 10 j.lM Cypate
concentration were added to the media containing cells and incubated for 2 hrs assuming
that longer reaction time will provide enough reaction time for lower uP A concentration.
Since the cleaving of short spacer should takes place in the cell culture medium where the
uPA is present, the fluorescence from the media was monitored (Fig. 36). For this study,
a Pear Imager (Licor) was used to measure the fluorescence, with excitation 780 nm and
the emission was detected from 805-830 nm.
The fluorescence of GNP-SSP-Cy in the media without cells was measured as a
control, and the fluorescence was at the noise level (5.2 RFU). In the media from the
MCF-7 (uPA-) cell culture, the fluorescence became very high (183 RFU), indicating the
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presence of uP A or some other biomolecules that cleaves the short spacer in the cell
media (as shown in the ELISA result).
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Figure 37. Fluorescence of GNP-SSP-Cy in media without cells, with
MDA-MB-231 cells, and with MCF-7 cells after 2 hr incubation. ExlEm:
780/805-830 nm

It is speculated that, a very long reaction time (2 hrs) allowed the low level of

uPA in MCF-7 to react with the short spacer. In the media of MDA-MB-231 cells the
fluorescence became 210 RFU, 15% higher than the one in the media of MCF-7 (uPA-)
cells. For further studies, a study for the time dependent fluorescence restoration is
suggested to be performed.

(b) Fluorescence of GNP-LSP-mCy in cell lines

The well performing GNP-LSP-mCy with the 8.0 nm GNP core showed the
fluorescence level twice of that of the mCy alone (Fig. 27). The well performed GNP-

LSP-mCy was tested in cell lines of MCF-7 and MDA-MB-231 , by Dr. Sharon Bloch in
the Achilefu group. It should be noted that this experiment should not be affected by uP A
because there is no short spacer in this entity. The cell uptake of GNP-LSP-mCy in this
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experiment is non-specific. The cell lines were treated with mCy and GNP-LSP-mCy at
the same mCy concentration. Then the cells (not the media) were imaged by the NIR
fluorescence microscope (Fig. 38) and the fluorescence was quantified by a photon
counter built in the microscope, at Ex/Em 780/830 nm, 1, 3 and 24 hrs after the treatment
(Fig. 39).
For both cell lines, and at all incubation time, the fluorescence of cell treated with

GNP-LSP-mCy was significantly higher (>= 10 times) than that with mCy, possibly due
to both fluorescence enhancement and higher cell uptake rate of GNP-LSP-mCy than
mCy due to the nano-size of the particle. The fluorescence ofmCy or GNP-LSP-mCy in
two cell lines is at a similar level, because as previously described, this product does not
have a specificity.
MCF-7
m-Cypate

MDA-MB-231

GNP-LSP-mCy

m-Cypate

GNP-LSP-mCy

1 hr

3 hr

24 hr

Figure 38. Fluorescence of Cypate and GNP-LSP-mCy in (a) MCF-7
(uPA-) and (b) MDA-MB-231 (uPA+) cells, 1, 3 and 24 hrs after the
treatment (performed by Dr. Sharon Bloch)
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Figure 39. Fluorescence of Cypate and GNP-LSP-mCy in (a) MCF-7
(uPA-) and (b) MDA-MB-231 (uPA+) cells, 1, 3 and 24 hrs after the
treatment (performed by Dr. Sharon Bloch)
In general, these results suggest that GNP-LSP-mCy can provide high contrast in
the cells, by enhancing the fluorescence of Cypate or by increasing the cell uptake rate or
probably by both.
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CHAPTER V
CONCLUSIONS

A. Theoretical Analysis on Fluorescence Alteration by GNP
A thorough analysis on the fluorescence alteration by GNP was performed for the
fluorophores frequently used in the biomedical research to understand how the system
parameters (the GNP size, Ex/Ern wavelengths and intrinsic quantum yield of the
fluorophore) and the distance between a fluorophore and a GNP affect the fluorescence
output.
To acqUlre fluorescence quenching effect, the fluorophores with the Ern
wavelength near the GNP plasmon resonance peak are good candidates. For the
fluorophores with Ern wavelengths sufficiently longer than the GNP resonance peak (e.g.,
far-red or NIR fluorophores), to achieve the same level of quenching, the distance
between the GNP and the fluorophore needs to be very short (e.g., < 2 nrn). With bigger
GNPs, for the same level of quenching, the distance between the fluorophore and the
GNP needs to be shorter.
The fluorescence enhancement is effective only if the Ern wavelength of the
fluorophore is sufficiently longer than the GNP resonance wavelength. The fluorophore
with lower quantum yield have a greater potential for fluorescence enhancement. The
GNP size needs to be sufficiently large to enhance fluorescence effectively. Bigger GNPs
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provide greater maximum fluorescence enhancement, and for bigger GNPs, the distance
for the maximal enhancement is shorter than that for the smaller GNPs.
The theoretical study results are highly beneficial for designing fluorescence
manipulation by GNPs for the fluorophores.

B. Development of NIR fluorescent contrast agent for specific cancer detection

An NIR contrast agent for highly sensitive and specific breast cancer detection
was developed, utilizing both the fluorescence quenching and enhancing ability of GNPs.
The fluorophore was conjugated to a GNP via two molecular spacers. One was short for
the fluorescence quenching and the other was long for the maximum enhancement. The
short spacer contains a G-G-R motif, uPA (enzyme secreted by breast cancer) substrate.
The NIR fluorophore Cypate was used because NIR can penetrate tissue deeper than the
visible light and is a derivative of the FDA-approved ICG with functional groups for
conjugation. The GNP is also conjugated with targeting molecule to guide the contrast
agent to the cancer site. Normally this agent is not to emit fluorescence because of the
short spacer. The short spacer is cleaved when the contrast agent is delivered to the
cancer site by the targeting molecule where uPA is present and the distance between the
Cypate and the GNP is controlled by the long spacer length, and thus the fluorescence is
emitted at an enhanced level.
The fluorescence quenching and restoration of Cypate conjugated to GNP via the
short spacer was studied. For the Cypate conjugated 3.7 and 8.0 nm GNPs via the short
spacer (2.5 nm, estimated by molecular simulation), the fluorescence was quenched by 96
and 95%, respectively. When uPA was applied, the fluorescence was restored. A high
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GNP concentration in the solution appeared to quench the fluorescence of the Cypate
released from the GNP. For the GNP concentration of at 2.5 nM in the solution, 74% of
the fluorescence was restored.
Cypate fluorescence enhancement by GNPs at 3.7, 8.0, and 16.4 nm was studied
using the spacers [HS-(CH2)mPEGn-ONH2] with a length range of 3.2-4.6 nm (m=12 or
16, n=4, 6, or 8). GNPs at 3.7 nm appeared to be too small to enhance Cypate
fluorescence. The spacer HS-(CH2)12PEG6-0NH2 (3.9 nm) provided the highest
fluorescence among the GNP sizes tested. With the GNPs of size 8.0 and 16.4 nm, the
fluorescence was enhanced up to 2.0 and 3.6 times, respectively, with the spacers tested.
Experimental study results qualitatively agreed with the theoretical estimation,
although the spacer lengths estimated by molecular simulation were

1~2

nm longer than

the distance in the theoretical result.
The performance of the novel dual spacer, containing both the short spacer section
with the uPA substrate motif and the long spacer section for the maximal enhancement,
was tested for the 8.0 nm GNP. The Cypate fluorescence was quenched by 93% when the
dual spacer was conjugated with the GNP. With the uPA application, the fluorescence
increased up to 1.8 times of the control.
The sell study was performed with the contrast agent with the short or long
spacers using two breast cancer cell lines, MCF-7 (uPA-) and MDA-MB-231 (uPA+). For
the contrast agent with the short spacer (GNP-SSP-Cv). the Cypate conjugated to 8.0 nm

GNP via short spacer was tested. The fluorescence of GNP-SSP-Cy was expected to
increase from a quenched level only in the media with uPA+ cells. However, in the uPA
quantification for both cell lines, it appeared the MCF -7. The results showed that in the
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media without cells, the fluorescence of GNP-SSP-Cy was verly low (5 RFU). In the
media with MCF -7 and MDA-MB-231 cells with the reaction time of 2 hours, the
fluorescence increased to 183 and 210 RFU, respectively. The reason of the increase
fluorescence in the MCF-7 cell medium might be due to small amount of uPA secretion
by MCF -7 cells. For the contrast agent with long spacer, the Cypate conjugated to 8.0
nm GNP via the long spacer providing the highest enhancement was applied to MCF-7

and MDA-MB-231 cells. The fluorescence of the cells with GNP conjugated Cypate via
the long spacer was 10 times higher than that of the cells with only Cypate. The higher
fluorescence may be a result by both the fluorescence enhancement and by the high cell
uptake rate caused by the GNP.

In terms of the utility of the study results they provide the information on how
GNPs alter the fluorescence of fluorophores, which can be beneficially utilized for the
fluorescence alteration in biosensing and imaging. The optical contrast agent developed
here has a high sensitivity by enhanced signal. The targeting molecules and the enzymetriggered fluorescence emission offer dual specificity and also characterize the cancer
type, which can be used for cancer diagnosis as well as cancer detection. This unique
construct provides the biomarker-specific emission as specific as FRET or molecular
beacon, but with higher sensitivity, without the restriction for DNA/RNA segments only.
The design of the contrast agent can also be used in biosensing/imaging with any
enzyme-substrate combination. The surface of GNPs can also be treated with cancer
drugs for the cancer treatment as well as detection/diagnosis.
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CHAPTER VI
FUTURE WORK

A. Completion with Targeting Molecules
The contrast agent in this study is designed to have targeting molecule for cancerspecific delivery. A breast cancer drug Tamoxifen (Tam), and a monoclonal antibody
Herceptin (Her) are currently being tested for targeting ER+ or HER2+ breast cancer,
respectively. The targeting ability of the GNP-rSP-mCy with Tamoxifen (GNP-rSPmCy/Tam)or Herceptin (GNP-rSP-mCy/Her) are being studied. The performance of the
final GNP products are suggested to be tested in various breast cancer cell lines.
Tamoxifen and Herceptin have been used for breast cancer therapy. Therefore,
therapeutic functions of the contrast agent are also suggested to be studied.

B. Application of the Concept for Other Target Enzyme
The contrast agent developed in this study is a model system for breast cancer
imaging. In future, the enzyme-triggered fluorescence mechanism can be applied for
other enzyme detection by replacing the uPA substrate motif in the short spacer to the
respective substrate of the target enzyme in biosensing or bioimaging.
For biosensing which has less requirement on tissue penetration of the
fluorescence or the safety of the fluorophore, many other fluorophores or quantum dots

107

may be used. It is suggested that simultaneous multi-enzyme detection system be
developed by using a mixture of contrast agents, in which each contrast agent is for the
detection of a particular enzyme, with a fluorophore emitting fluorescence at a different
wavelength from others.

c. Development of multi-functional nano-contrast agent
Our research group has been studying iron oxide nanopartic1e-induced
hyperthermia using alternating electromagnetic (AEM) field for cancer treatment for
years. In the future, the contrast agent developed in this study can incorporate iron oxide
nanopartic1e as a core with a gold shell to provide both optical detection and non-invasive
hyperthermia within one-entity. Iron oxide nanopartic1e can also be used as MRI contrast
agent. Gold nanoshell can be used for X-ray/CT imaging contrast agent due to increased
scattering. The gold surface can be treated with targeting molecule and cancer drugs.
Therefore, this multi-functional design may provide non-invasive, targeted cancer
delivery and multi-modality imaging contrast for sensitive and specific cancer detection,
and multi-treatment (drug and hyperthermia) within one entity.
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APPENDIX I
GOLD NANOPARTICLES FOR
SENSITIVITY ENHANCEMENT IN REAL-TIME, IMMUNOOPTICAL CARDIAC MARKER SENSING

A. BACKGROUND
1. Four Cardiac-marker Sensing System for AMI Diagnosis

Acute myocardial infarction (AMI) is the world's leading cause of morbidity and
mortality. It is also a disease with a high rate of misdiagnosis due to the low sensitivity
of the current diagnostic tools used in the emergency room [Wu, et al., 1999; Pope, et al.,
2000]. A better method for AMI diagnosis is to quantify the elevation of cardiac markers
in blood plasma [Bernard, et al., 1979]. Currently, the cardiac markers are usually
quantified in a central laboratory, and it often takes hours from when it is ordered till the
results are received. Due to the needs for urgent treatment of the disease nature, a rapid
and accurate point-of-care (POC) system is critical. The fiber-optic, fluorophoremediated, immuno-sensing system has demonstrated accurate, sensitive, rapid, and
reliable simultaneous quantification of various biomarkers [Wu, et al., 1999; Pope, et al.,
2000]. The Kang group has been developing portable, near-infrared, real-time multi
cardiac marker sensing system by immuno-optical sinsing. The four markers selected for
our sensing system were as follows: B-type natriuretic peptide (BNP) and C-reactive
protein (CRP) are crucial markers for the diagnosis of congestive heart failure and acute
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coronary syndromes [Maisel, et al., 2002; Sabatine, et al., 2002]; Myoglobin (MG) and
cardiac troponin I (cTnl) are important markers for early diagnosis of a heart attack
[Apple, et al., 1999].

Our research group has previously determined the clinically

important sensing range of the marker to be
4~40

nM for MG and

5.6~56

26~260

pM for BNP;

30~300

pM for cTnl;

nM for CRP [Tang, et al., 2005; Tang and Kang, 2006;

Tang et al., 2006], bOased on the assessment of the clinical results. For BNP and cTnI,
their concentrations in plasma at an early disease stage are only tens of pico molar level,
requiring extremely high sensitivity, which can be improved by enhancing the signal.

2. GNP Reagent for Fluorescence Enhancement

The Kang group has been studying to use GNPs in the fluorophore mediated,
fiber-optic biosensing to enhance the fluorescence to improve the sensitivity of the sensor
[Hong and Kang, 2006; Kang and Hong, 2006]. The sensor performs a fluorophoremediated sandwich immunoassay on the sensor surface, and the fluorescence intensity is
correlated with the analyte concentration in blood plasma [Kang et al., 1997; Spiker et
al., 1998; Kwon et aI., 2002; Baler et al., 2002].
In an attempt to enhance the sensitivity of the sensing system GNPs were applied
to the sensor surface after the sandwich formation, and the fluorescence intensity was
observed and compared with that without GNP application. The minimum distance
between the GNP and the fluorophore was adjusted by a self-assembled monolayer
(SAM) on the GNP surface. The effect of GNP size and SAM thickness was studied.
Among the GNP-SAMs tested (GNP size of 2, 5, and 10 nm and SAM thickness of 1, 2
and 3 nm), 5 nm GNPs coated with 2 nm SAMs (5 nm GNP-SAM2 nm) were found to
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be the best enhancer, and the enhancement level was up to 230%.
Hong and Kang [2006] also found that some solvents could also enhance the
fluorescence of a fluorophore without denaturing the antibody on the sensor surface, by
shifting the fluorophore excitation/emission wavelengths, and/or by changing the transcis isomerization direction, and/or by shrinking fluorophores tagged proteins, so that the
fiber received more fluorescence. They have tested various solvents and found that 1butanol and ethanol showed the highest and 2nd highest enhancement, respectively.
To maximize the enhancement effect, Hong and Kang [2006] mixed the two
enhancers, the GNP-SAM and the solvent, to form GNP reagent (GNPR). They have
tested the GNPR of 5 nmGNP-SAM2nm in ethanol with Alexa fluorophore (Alex-647)
for four-cardiac marker sensing and achieved sensitivity improvement by

1.5~3

times.

In this study, our effort was focused on further improving the sensitivity by using
GNPR with butanol. Improving sensitivity allows reducing of the sensor SIze and,
therefore, the sample and reagents volume (i.e., assay cost reduction), and also
portability.

B. MATERIALS, INSTRUMENTS AND METHODS

1. Sensor Preparation
For the cardiac markers and their respective monoclonal antibodies, BNP was
purchased from Bachem (Torrance, CA) and monoclonal IgG against human BNP was
from Strategic Biosolutions (Newark, DE). cTnI, MG, and CRP, and their antibodies
were obtained from Fitzgerald Industries (Concord, MA).
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Four cardiac marker biosensors were constructed, following the protocol
established by Tang et al. [2006]. Briefly the surface of four quarts fibers (Research
International, Inc.; Monroe, WA) were treated and immobilized with streptavidin
(Sigma!Aldrich, St. Louis, MO). 0.1 M ethanolamine (Sigma!Aldrich) was applied to
terminate the reactive function groups on the sensor surface. The monoclonal antibodies
(1 °Mab) against the respective markers were conjugated with biotin (Sigma!Aldrich) and
immobilized on the surface of fiber via streptavidin-biotin bond, and the sensors were
encased in a micro-sensing chamber. The fluorophore Alexa Fluor® 647 (AF647; max.
excitation/emission wavelengths, 649/666 nm) was from Invitrogen (Carlsbad, CA). The
respective second monoclonal antibodies (2°Mab) were conjugated with AF647
following the manufacture's instruction.

2. Assay Protocol with the Sensor

The emulated plasma was prepared 103 mg/ml human serum albumin (HSA;
Sigma!Aldrich) in the PBS buffered solution, because it provides similar physical
properties for sensing [Hong and Kang, 2006]. Samples with cardiac markers were
prepared by adding known amount of cardiac markers to the emulated plasma.
The cardiac marker assay was proceeded as follows: a sample was introduced into
the sensing chamber and incubated for 3 min with the sample circulating at a rate of 1.2
cm/sec. The sensor was then washed with phosphate buffered saline with 0.1 % Tween
20 (PBST, pH 7.4) for 1 minute in circulation to remove the unbound molecules in the
sample. Then the baseline fluorescence was measured using the fluorometer (Analyte
2000TM; Research International). The instrument has four sensing ports. AF647 tagged
2°Mab, at a concentration of 10 /lg/ml, was then applied to the chamber and incubated for
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4 minutes the reagent in the circulation mode to react with the bound analyte. For the
simultaneous four marker sensing, all four 2°Mabs were mixed and applied to the sensing
system. The sensor was washed with PBST for 1 minute and the second fluorescence
readings were taken.

The signal difference between this signal and the baseline

subtracted by the negative control is the signal intensity of the sample.
For preparation of the GNPR, 5nm-GNPs coated with citric acid were purchased
from Ted Pella (Redding, CA). I-butanol was purchased from Sigma/Aldrich. For the
sensing with a GNPR. When GNPR was used in sensing, there were slight changes in the
sensing protocol: For the baseline measurement, the GNPR was applied before the
sample incubation. For the signal by the sample, GNPRs were applied after the second
antibody was reacted with the analyte on the sensor surface. The difference between the
latter and the former was taken as the signal with GNPR. The enhancement was defined
as the fluorescence signal with the GNPR divided by the fluorescence from the sensor
without GNPR.

3. Microfluidic System and Automated Sensing Operation

The sensing chip and micro channel network of the sensmg unit were
microfabricated by the Chong H. Ahn group [Sohn, et al.,2005 and Hong, et aI., 2008].
The system includes a polycarbonate mother board with imbedded network of the
microchannels; a four-channel, plastic sensing module; a micro-solenoid pump (12 v, 50
).lL per stroke, 2 W); seven micro-solenoid valves (12 v, 280 mW, Lee Co.; Westbrook,
CT); a data acquisition (DAQ) card (USB-6008, 8 inputs, 12 bits, 10000 samples/s,
multifunctional 110, National Instruments; Austin, TX); and a drive circuit with a power
plug, a power switch, and a power LED.
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C. RESULTS AND DISCUSSION

1. Reduction in Sensor Size
Here, we have attempted to reduce the sensor size from 3 to 1.5 cm by using 5
nmGNP-SAM2 nm in butanol. Since BNP has the lowest sensing range among the four
cardiac markers, BNP sensor size was our main concern.
Figure API-1 shows the performance of the BNP sensors with the sensor size of
(a) 3 and (b) 1.5 cm, with and without GNPR, when the total sensing time was 15 min.
In terms of the signal intensity enhancement by GNPR, the signals were enhanced by 4
and 3 times for the 3 cm and 1.5 cm sensors, respectively. For the 1.5 cm, the signal
without GNPR was very low in the entire sensing range. The signal for the 1.5 cm sensor
with GNPR was approximately 40% of that of the 3 cm sensor. Nonetheless, the
correlation coefficient was 0.96 (0.95 for 3 cm sensor), and the signal to noise ratio (SIN)
was 4.1 (3.8 for 3 cm sensor), showing that the performance of the 1.5 cm sensor was still
satisfactory, but with less sample and reagent.
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3. Four Cardiac Marker Sensing by the Mini-sensor
Since the sensing performance of the 1.5 cm BNP sensor was satisfactory, the 1.5
cm sensor size was then tested for all four cardiac markers in the four sensor micro
sensing chip. The size of the sensing chip for four cardiac marker was reduced from 4 x 4
cm (for 3 cm sensors) to 2 x 2.5 cm (for 1.5 cm sensors) accordingly. A schematic
diagram of the chip is shown in Fig. API-2 . As previously shown by Hong, et aI. , [2008] ,
on the inner surface of the microchannel, bumps/baffles were microfabricated to create
local turbulence, to facilitate the analyte transport to the sensor surface.

The mini-

sensing chip requires a sample size of only 200 JlI , and therefore, only 0.5 ml of a blood
sample is needed for an assay.

Connector

Fiber-optic sensor
Inl et of fl ow
Sensing chip
r-~----------~~-.---

Sensor

----

4

Micro -bump

....

Flow direction

....... __ ..........

Outlet of flow

(b)

20mm
(a)

Figure API-2. (a) Schematic diagram of mini-sensing chip and
Enlarged diagram of a sensing chamber

(b)

Figure API-3 shows the performance of the four-cardiac marker sensors with and
without GNPR, when the entire senisng time was 15 min. For BNP and cTnI, the signal
range without using GNPR was only

3 ~30

pA. With GNPR, the signal was enhanced by

3 and 4 times, respectively. The SIN ratios were 4.1 and 4.5, and the correlation
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coefficients were 0.96 and 0.97, respectively.

For MG and CRP, the signal ranges

without and with enhancer were 4- 105 pA and 90- 400 pA, respectively. The signals
were enhanced by 5 and 2 times and the SIN ratios were 5.2 and 6.7 for MG and CRP,
respectively. As can be seen from these values, these two markers do not need enhancer.
But, since the four marker sensing needs to be done simultaneously with a single sample
and reagents, GNPR was applied for all four sensors.
All four 1.5 cm sensors showed linear relationships between the marker
concentration and the signal intensity, with correlation coefficients above 0.95 .
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D. CONCLUSIONS AND FUTURISTIC, PORTABLE ALL-IN-ONE DEVICE
Our MEMS based sensing device with mini-sensing chips (2 x 2.5 cm) and novel
gold nanoparticle reagent can accurately quantify four cardiac markers simultaneously at
clinically significant concentration ranges within 15 min, requiring a plasma sample
volume of only 200!il. The entire sensing system may be converted to be a highly
portable, all-in-one, point-of-care (POC) sensing device. For the next step, the system
may be further optimized considering both sensitivity, time, and cost, by comparing the
performance of GNPR with ethanol and butanol in the mini-sensing system.
In the future, the current sensing system of the fluorometer, micro fluidic flow
control unit, display monitor and input keyboard may be put into a highly portable, all-inone device at a size of 30 x 20 x 15 cm (Fig. API-4). With disposable sensing chip and
sample reagent containers, a four cardiac marker sensing may be performed withing 15
min in an emergency room or even in an emergency-medical-service vehicle.

Figure API-4. Schematic design diagram of all-in-one four cardiac marker
sensing device.
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APPENDIX II
HOLLOW GOLD NANOSPHERE FOR
CONDITIONAL FLUORESCENCE QUENCHING

A. BACKGROUND
Solid, spherical gold nanoparticles (GNPs) are known to generate surface
plasmon field resonance around 520 nm [Eustics and EI-Sayed, 2006]. Other gold
nanostructures such as shells, thin films, nanorods, and triangles also generate strong
surface plasmon field by the visible light, and the wavelength of their absorption peaks
are strongly dependent on the dimension of their nanostructure [Hu, et al., 2006]. Dr. Jin
Z. Zhang's group at the University of California, Santa Cruz, California, developed
hollow gold nanospheres (HGNs) with various plasmon resonance peaks in the entire
range of the visible and NIR wavelengths, by varying the diameter-to-wall thickness ratio
[Hu, et al., 2006; Schwartzberg, et al., 2006].
HGNs tuned for NIR feature several advantages. Their strong absorption in NIR
makes the HGN an effective absorption contrast agent for NIR imaging. For example, the
extinction coefficient of hemoglobin, one of the strongest bio-chromophore in NIR, is in
the range of 3 x 102 /cm M [Kim, et aI., 2005]. From our measurement and calculation,
the extinction coefficient of the HGNs that we currently use is in the range of 5-12 x
lOlD/cm M, which is approximately 8 orders of magnitude higher than that of
hemoglobin. Because of this high absorption in NIR they were used for NIR
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hyperthermia very effectively [Ji, et ai., 2007; Lu, et ai., 2009]. GNPs are also strong
scatterers for X-ray and therefore HGNs can be effective X-ray/CT contrast agents
[Zhang, 2010]. These multiple properties allow HGNs be excellent candidates for both
cancer detection (NIR fluorescence/X-ray/optical imaging) and treatment.
According to our theoretical analysis on fluorescence quenching by GNP [Chapter
IV, section 1], when the Ex/Em wavelengths of a fluorophore are near the plasmon
resonance wavelength of the particle, the fluorescence is strongly quenched. Therefore,
HGNs with plasmon resonance peak in the far red or NIR region can be a highly effective
quencher for NIR fluorophores.
Here, the conditional emission of Cypate fluorescence was studied utilizing
HGNs, using the short spacer containing the -G-G-R- motif to be cleaved by uPA
[Chapter IV, section 2]. HGNs studied were: (i) HGN 654 : The particle has the outer
diameter of 41 run with the hollow center diameter of 28 nm (28/41 run). Its plasmon
resonance peak is at 654 run; (ii) HGN 786 : The hollow and outer diameter are 43 and 53
nm, respectively, and the plasmon resonance peak is at 786 run.

B. MATERIALS, INSTRUMENTS AND METHODS
HGN 654 (3.32x10-6 !J,M) and HGN 786 (2.49x10-6 !J,M) stabilized with citric acid in
water were provided by the Zhang group at the University of California, Santa Cruz.
Cypate and Cypate conjugated short-spacer HSCH2CH2NH-G-G-R-G-G-G-NH2 (sSPCy), sPEG and uPA were as described in the materials section (Chapter III).
HGN-sSP-Cy was synthesized and purified using the same methods used for
synthesizing GNP-sSP-Cy (Chapter III). For HGN 654 , the concentration of HGN 654 and

134

Cypate in the HGN 654 -SSP-Cy was quantified by the absorption at 654 and 780 run,
respectively. For HGN 786 -sSP-Cy because the absorption of HGN786 and Cypate
significantly overlap, we were not able to quantity these by the spectroscopic method.
The fluorescence of the sample in O.OOIM PBS buffer was measured in a 96-well
Uniplate using a Spectra Gemini XPS fluorometer at the excitation and emission
wavelengths of 780 and 830 run, respectively.

C. RESULTS AND DISCUSSION
1. Fluorescence Quenching and Restoration of HGN 654 -SSP-Cy

The fluorescence of HGN 654 -SSP-Cy was measured and compared to that of the
free sSP-Cy at the same sSP-Cy concentration (5 !J.M); (Fig. 1). At this Cypate
concentration the HGN654 concentration was 3.5 x 10-3 nM.
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In HGN 654 -SSP-Cy the Cy fluorescence was quenched by 84%. Compared to sSPCy with 3.7 or 8 nm GNPs (with GNP concentration 31 or 7 nM, quenched by 96 or 95%,
respectively) this was slightly less.
After uPA was added (1030 unit/mL, at a sufficient amount) to the HGN654 -SSPCy sample, the fluorescence was restored to 80% of the free Cypate.

2. Fluorescence Quenching and Restoration of HGN 786 -SSP-Cy
The absorption peak (786 nm) of HGN 786 is very close to the emISSIOn
wavelength of Cypate (830 nm). HGN786 and Cypate in the final product (HGN786 -SPCy) could not be determined because the HGN absorption peak highly overlaps with that
of Cypate. Therefore, only the absolute fluorescence before and after adding uP A were
obtained (Fig. 2), without the relative fluorescence values.
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The fluorescence ofHGN 786 -SP-Cy without uPA was 0.52 RFU, at the lower limit
of the instrument, suggesting that the Cypate fluorescence was almost or completely
quenched by HGN 786 • When uPA was added to the sample, the fluorescence increased to
5.0 RFU. Assuming that both HGN654 and HGN 786 have similar restoration rate, the
fluorescence of HGN 786 -SP-Cy is 53% lower than that of HGN 654 -SP-Cy, and HGN786
appears to quench more effectively than HGN 654 does, due to its stronger absorption at
the Cypate emission peak's wavelength.

D. CONCLUSIONS
The two HGNs, which absorption wavelengths are adjusted in NIR, especially
HGN 786 , demonstrated an excellent ability for quenching Cypate fluorescence when
Cypate is conjugated on them via the short spacer. The conditional fluorescence emission
in the presence of the cancer-secreting enzyme was well confirmed. This conditional
emission property is especially important because it adds an imaging-contrast ability to
the nano-entity that already possesses multi-functions of NIR absorption contrast; X-ray
scattering contrast; and photo-thermal property.
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